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Summary 
Type I signal peptidases (SPasesI) play an indispensable role in the export of secretory 
proteins by cleaving off the N-terminal extensions called signal peptides from proteins 
that are translocated across biological membranes. The bacterial SPasesI are also 
regarded as attractive antibiotic targets due to their essentiality, relative accessibility and 
their unique and conserved catalytic mechanism. Of the two genes encoding homologues 
of type I signal peptidase in Staphylococcus aureus, spsA and spsB, we focused on the latter 
that encodes the catalytically active and essential type I signal peptidase, SpsB. The aim of 
this work is the biochemical investigation of the enzyme SpsB, development of in vitro 
screening systems and finally high-throughput screening of compounds in the search for 
new inhibitors.  
 
In the first stage, we demonstrated the in vitro activities of the full length SpsB and N-
terminally truncated derivative of SpsB (tr-SpsB) on a native preprotein substrate, 
immunodominant staphylococcal antigen A UpreUcursor (pre-IsaA). The ability of the 
truncated SpsB to cleave the preprotein substrate implies that the transmembrane 
segment is not essential for SPase activity. The specific enzymatic activities of the full-
length and the tr-SpsB were determined using a FRET assay involving an internally 
quenched synthetic decapeptide designated as SceD peptide. The kcat/KM value of the 
full-length SpsB was 1850 M-1s-1, approximately 30-fold higher in comparison with tr-
SpsB.  This shows that the transmembrane segment residues, although not essential, are 
required for optimum activity of the enzyme. 
  
In the second stage, we analyzed the in vitro behaviour of the full-length SpsB. The pH-
rate profile for SpsB revealed an optimum pH of approximately 8. The apparent pKa 
values for the free enzyme were determined to be approximately 6.6 and 8.7 with 
possibly another pKa around 11.8. In common with the other SPasesI characterized so 
far, SpsB undergoes intermolecular self-cleavage, following the (-3,-1) rule for signal 
peptidase recognition and cleavage. The self-cleavage of SpsB resulted in an N-terminally 
truncated product with the catalytic Ser as the penultimate residue but was inactive in the 
FRET assay. By comparing the amino acid sequences and activities of the self-cleavage 
product of SpsB and tr-SpsB, we suggest that 9 amino acid residues immediately 
Summary 
 viii
preceding the catalytic Ser, that are lacking in the self-cleavage product, are essential for 
SpsB activity.  
 
In the third stage, we demonstrated in vitro inhibition of SpsB in the FRET assay as well 
as in the preprotein processing assay, using known SPase inhibitors. The FRET assay was 
standardized in a 96-well format, evaluated by screening compounds and assessed for 
quality and reproducibility. The preprotein assay served as a secondary assay to test 
potential inhibitors.  
 
In the final stage, the FRET assay was adapted in a 384-well format and transferred to a 
high-throughput screening facility. Approximately 27,000 diverse small molecule 
candidates were screened in the FRET assay against SpsB. Although, the quality of the 
screen reflected the robustness of the assay (with an average Z’ value of 0.73), no potent 
inhibitors were obtained. Further analysis led to finding a weak inhibitor (code JRD2189) 
of SpsB with IC50=51 µM in the FRET assay. The compound was also active against E. 
coli LepB but could not inhibit preprotein processing.  
 
In short, we have analyzed the properties of SpsB and developed in vitro systems to 
facilitate the search for new classes of antibiotics against S. aureus. 
 ix 
Samenvatting 
Type I signaalpeptidases (SPasesI) spelen een essentiële rol in eiwitsecretie aangezien 
deze enzymen verantwoordelijk zijn voor de afsplitsing van de N-terminale 
signaalpeptiden van secretorische eiwitten na hun transport over een biologische 
membraan. Bacteriële SPasesI worden beschouwd als een interessant antibacterieel 
doelwit omwille van hun essentieel karakter, omdat ze relatief gemakkelijk toegankelijk 
zijn voor kleine moleculen en hun katalytisch mechanisme uniek en geconserveerd is. In 
dit proefschrift hebben we SpsB, één van de twee SPaseI-homologen die aanwezig zijn in 
Staphylococcus aureus, bestudeerd. In tegenstelling tot SpsA is SpsB katalytisch actief en van 
essentieel belang voor S. aureus. Het doel van dit proefschrift was een biochemische 
karakterisering van SpsB en de ontwikkeling van in vitro screeningtesten, om finaal via 
high-throughput screening SpsB-remmers te identificeren. 
 
In het eerste deel van dit proefschrift hebben we aangetoond dat zowel het volledige (fl-
SpsB) als een N-terminaal ingekorte vorm (tr-SpsB) van SpsB in vitro-activiteit vertonen 
ten opzichte van het natieve preproteïne-substraat, immunodominant staphylococcus 
antigen A UpreUcursor (pre-IsaA). Het vermogen van de ingekorte vorm van SpsB om het 
preproteïne-substraat te klieven impliceert dat het transmembranair domein niet 
essentieel is voor de activiteit van SpsB. De specifieke enzymatische activiteit van fl-SpsB 
en tr-SpsB werd bepaald d.m.v. Fluorescentie Resonantie Energie-Transfer (FRET), met 
een gemerkt synthetisch decapeptide, het SceD peptide. De kcat/KM-waarde van fl-SpsB 
was 1850 M-1s-1, ongeveer 30 keer hoger dan de kcat/KM-waarde die voor tr-SpsB werd 
verkregen. Dit toont aan dat aminozuren in het transmembranair domein van SpsB niet 
essentieel, maar toch belangrijk zijn voor optimale enzymatische activiteit. 
 
In het tweede deel van dit proefschrift hebben we fl-SpsB verder in vitro biochemisch 
gekarakteriseerd. Het pH-profiel van de SpsB-activiteit vertoonde een optimum bij pH 8.  
De schijnbare pKa-waarden voor het vrije enzym waren ongeveer 6.6 en 8.7, met mogelijk 
een tweede pKa rond 11.8. Net zoals de andere SPasesI die tot nog toe zijn 
gekarakteriseerd, ondergaat ook SpsB intermoleculaire zelfsplitsing volgens de (-3,-1)-
regel voor signaalpeptidase-herkenning en -splitsing. Zelfsplitsing van SpsB resulteert in  
een N-terminaal ingekorte vorm (sc-SpsB) met het katalytische Ser als het voorlaatste 
aminozuur. Deze zelfgesplitste proteinevorm bleek geen SPase-activiteit te vertonen in 
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de FRET-test. Door de aminozuursequenties en de activiteit van het zelfsplitsing product 
en tr-SpsB te vergelijken, lijkt het ons aannemelijk dat de 9 aminozuren die het 
katalytische Ser voorafgaan (en die ontbreken in het zelfsplitsingsproduct) essentieel zijn 
voor SpsB-activiteit. 
 
In het derde deel van dit proefschrift hebben we gekende SPase-remmers gebruikt om de 
in vitro-remming van SpsB aan te tonen, en dit zowel d.m.v. de FRET-test als d.m.v. een 
test waarbij de splitsing van een preproteïne door SpsB kan worden gevolgd. De FRET-
test werd gestandardiseerd in een 96-well-formaat en geëvalueerd voor de screening van 
kleine moleculen door de kwaliteit en de reproduceerbaarheid van de test na te gaan. De 
test waarbij de splitsing van een preproteïne door SpsB wordt gevolgd, werd als een 
bijkomende test gebruikt om potentiële SpsB-remmers te bestuderen. 
 
In het laatste deel van dit proefschrift werd de FRET-test aangepast naar een 384-well-
formaat om gebruikt te kunnen worden voor high-throughput screening. Ongeveer 
27000 kleine moleculen werden zo getest tegen SpsB. Ondanks de robuustheid en de 
hoge kwaliteit van de test (met een gemiddelde Z’-waarde van 0.73) werden geen sterke 
SpsB-remmers gevonden. Na verdere analyse werd een zwakke remmer (code JRD2189) 
geïdentificeerd met een IC50 van 51 µM in de FRET-test. Dit molecule was ook actief 
tegen E. coli LepB, maar was niet in staat om de splitsing van een preproteïne door 
SPaseI te remmen. 
 
We kunnen dus concluderen dat we in dit werk SpsB biochemisch hebben 
gekarakteriseerd en in vitro-testen hebben ontwikkeld voor het identificeren van een 
nieuwe klasse van antibiotica gericht tegen S. aureus.   
 1 
Chapter 1: Introduction 
1.1 The need for new drugs 
Bacterial and parasitic diseases are the second leading cause of death worldwide. The 
treatment of bacterial infections has become increasingly challenging as antibiotics that 
have been saving millions of lives are losing effect. This is mainly due to their overuse or 
misuse contributing to the emergence of multiple drug-resistant strains. Of major 
concern is multidrug resistance in (i) common respiratory pathogens including 
Streptococcus pneumoniae, Mycobacterium tuberculosis (ii) Gram-negative bacilli (eg: Pseudomonas 
aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae) and (iii) Staphylococcus aureus. In 
addition, an increase in the use of indwelling and prosthetic devices has added biofilms 
(communities of sophisticated matrix-encased, surface-attached bacteria that exhibit a 
distinct phenotype) in which bacteria are less sensitive to antibiotics, to the already 
existing problem. On the other hand, the number of different antibiotics available to 
treat infections is dwindling and there are only a handful of new antibiotics in the drug 
development pipeline (Devasahayam et al., 2010). Therefore, there is an urgent need for 
new drugs preferably with new modes of action to potentially avoid cross-resistance 
(Payne, 2008). Of late, there has been an increase in interest in identifying and 
characterizing non-conventional antibiotic targets including the components of the 
bacterial protein secretion pathway such as SecA, a protein translocation ATPase and the 
type I signal peptidases (SPasesI), which are key enzymes in preprotein processing 
(Stephens & Shapiro, 1997). This work focuses on the latter component of the secretion 
machinery. 
1.2 An overview of bacterial protein secretion  
In bacteria, approximately 25-30 % of the proteins synthesized are destined to function 
at the cell envelope or outside. These proteins are transported from their site of synthesis 
(cytoplasm at the ribosomes) across the cytoplasmic membrane in three steps: targeting, 
translocation and release/maturation. The majority of proteins destined for 
transmembrane transport are synthesized as precursors or preproteins with a small 
amino-terminal extension called the signal peptide, which apart from other functions, 
serves primarily as a zip code for sorting and targeting (von Heijne, 1998). The process 
of targeting and translocation is accomplished by the general UsecUretion pathway (Sec 
Chapter 1 
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pathway) which is essential and universal in bacteria or the twin- Uar Uginine translocation 
(Tat pathway) that also exists in several bacteria (Natale et al., 2008). Both pathways 
consist of separate targeting components and in each case, a membrane-embedded pore 
through which the preprotein is translocated (the translocon), is present. A major 
difference between the two pathways is that, while the former translocates unfolded 
proteins, the latter serves in transporting folded proteins across the membrane. During 
or shortly after translocation of the preproteins, the hydrophobic signal peptides are 
cleaved off by enzymes, called the signal peptidases, ensuring their release from the 
membrane (Paetzel et al., 2002b). In a major role, the type I signal peptidase (also known 
as leader peptidase and abbreviated as SPaseI or Lep or Sip), a membrane-bound serine 
endopeptidase, processes non-lipoproteins thereby enabling them to reach their final 
destination. In a minor role, SPase II or the lipoprotein signal peptidase (Lsp) processes 
lipid-modified lipoprotein precursors. The type IV SPase (SPase IV) specializes in the 
cleavage of type IV preprepilin and prepilin like proteins. Unlike SPaseI, neither of the 
latter enzymes are essential for cell viability (Paetzel et al., 2002b). In Gram-positive 
bacteria fully translocated proteins are exported to the cell wall or the surrounding 
medium. In Gram-negative bacteria, these proteins are released into the periplasm, 
integrated into or transported across the outer membrane or finally exported to the cell 
wall or the outside medium. Bacteria also possess additional dedicated protein secretion 
systems designated type I to type VII secretion systems (or T1S to T7S) (Bitter et al., 
2009; Economou et al., 2006; Thanassi & Hultgren, 2000). These systems mainly function 
in the translocation and secretion of proteins across the double hydrophobic membrane 
barriers as in Gram-negative bacteria. Some of the additional systems also involve the Sec 
or Tat machinery for transport across the cytoplasmic membrane, for example as in the 
case of T2S, T4S and T5S.  
 
1.2.1 Signal peptides 
Signal peptides have an average length of 20 amino acid residues (generally longer in 
those from Gram-positive 
bacteria) and strikingly show 
no conservation of sequence. 
However, three distinct 
regions can be recognized 
UFigure 1.1U: Schematic representation of the tripartite 
structure of a signal peptide showing the SPase 
recognition sequence and cleavage site. 
N C
n-region h-region c-region
SPase cleavage site
+
mature protein
AXA
-3  -1
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which are a positively charged amino-terminal (n-region), a hydrophobic core (h-region) 
and a polar carboxyl terminal (c-region) (von Heijne, 1990) (Figure 1.1). The h-region is 
the largest part of the signal peptide and is formed by a stretch of hydrophobic residues 
that seem to adopt an α-helical conformation and often has a helix-breaking Gly or Pro 
in the middle of the region that might facilitate signal peptide insertion into the 
membrane (de Vrije et al., 1990). The n-region is composed of a positively charged 
stretch of polar residues which appears to interact with the negatively charged 
phospholipids in the membrane and determines the orientation of the signal peptide 
thereby obeying the “positive-inside rule” (Dalbey, 1990; von Heijne, 1992).  The c-
region usually has a helix-breaking Pro or a Gly residue at position -4 to -6 relative to the 
SPase cleavage site and ends with small, neutral residues (most commonly Ala) at 
positions -1,-3 which has been referred to as the “Ala-X-Ala” SPase recognition 
sequence. The c-region faces the extracytoplasmic side of the membrane after 
translocation and must have a β-stranded conformation in order to be recognized by the 
SPase (van Roosmalen et al., 2004). The non-lipoprotein signal peptides share the same 
generic structure but the Tat signal peptides differ from the Sec signal peptides in certain 
aspects, notably in the presence of two invariant arginines, the eponymous twin-arginine 
motif at the interface of the n- and h- regions (Natale et al., 2008). Besides the non-
lipoprotein signal peptides, which are processed by SPasesI, there are two other types of 
signal peptides namely lipoprotein and prepilin signal peptides. Lipoprotein signal 
peptides also have the n-, h- and c- regions but in addition possess the lipobox at the c-
region that has information for lipid modification at the +1 cysteine residue. After lipid 
modification of the +1 cysteine the signal peptide is cleaved from the preprotein by 
SPasesII. Preprepilin signal peptides are present in type IV prepilins and prepilin-like 
precursors that form a part of the type II secretion system. These signal peptides are 
characterized by a short basic region without any hydrophobic domain and are processed 
by type IV prepilin SPases (Paetzel et al., 2002b). 
 
A comparative analysis of 107 experimentally determined E. coli SPase substrates (Choo 
et al., 2008) revealed a high conservation of amino acid residues at positions P3 (-3) and 
P1 (-1). In particular, position P1 is dominated by small, hydrophobic, and neutral amino 
acids, with Ala being the predominant residue (92 %), followed by Gly (9 %). Position P2 
shows a strong preference for bigger side chains with 87 % possessed by medium- or 
large-sized residues at this location. Position P3 also shows a preference for hydrophobic 
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UFigure 1.2 U: A schematic view of preprotein targeting, translocation and 
processing by the type I SPase resulting in the release of the mature 
protein. 
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residues and contains mainly small amino acid residues but can also accommodate both 
medium and large residues. Only 50 % of the sequences analyzed contained the 
consensus Ala-X-Ala recognition motif, where as 18% contained Val-X-Ala recognition 
sequence.  
 
Signal peptides are functionally important because they are recognized by the targeting 
components of the secretion machinery and passed onto the translocation machinery for 
transmembrane transport (van Roosmalen et al., 2004). They serve as topological 
determinants for the preprotein in the membrane. In addition, they inhibit or retard 
folding of the nascent chains thus retaining the preproteins in a translocation-competent 
state and also avoiding the activation of potentially harmful enzymes inside the cell. The 
signal peptides are cleaved off by the signal peptidases and are subsequently degraded by 
enzymes called signal peptide peptidases (Paetzel et al., 2002b).  
 
1.2.2 The Sec and the Tat pathway 
The process of protein translocation is most extensively studied in E. coli. Briefly, the Sec 
system consists of 
protein targeting 
components, a 
membrane- 
embedded, protein- 
conducting channel 
(PCC) comprising 
three proteins 
(SecY, SecE and 
SecG) which form 
the Sec translocase 
and a peripherally 
associated, ATP-
driven motor protein SecA. SecD, SecF and YajC form the translocon-associated 
complex and YidC is involved in membrane protein integration and folding (Figure 1.2). 
The central components of the Sec translocation system of Gram-positive and Gram-
negative bacteria show a high degree of conservation, suggesting similar functions and 
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working mechanisms. However, certain differences can be identified, for example the 
absence of a secretion-specific, chaperone-like SecB in Gram-positive bacteria. The 
targeting of secretory proteins in the Sec pathway occurs either post or co-translationally. 
In case of the former, the fully synthesized preprotein detaches from the ribosome and is 
directed to the Sec translocase guided by SecB, which maintains the translocation-
competent unfolded state. In co-translational targeting the signal recognition particle 
(SRP) binds to the signal sequence of the secretory protein while it emerges from the 
ribosome and the entire ternary complex of SRP/ribosome/nascent secretory protein 
chain is targeted to the Sec translocase with the aid of signal recognition particle receptor 
(SR or FtsY). SecA accepts the unfolded proteins and threads them through the 
transmembrane channel (PCC) using the energy provided by ATP and the proton-motive 
force (PMF) (Ito & Mori, 2009; Natale et al., 2008). In the Tat pathway, 
pretranslocational folding is necessitated by the incorporation of metallo-factors, 
assembly into oligomeric complexes, and presumably rapid folding kinetics (Panahandeh 
et al., 2009). The Tat system consists of two or three membrane-integrated subunits 
namely TatA and TatC (especially in Gram-positive bacteria) or TatA, TatB and TatC 
that together form a receptor and a protein-conducting machinery for Tat substrates. 
TatC and TatB form a complex that is involved in recognition of Tat signal sequences 
and their insertion into the membrane, while TatA mediates the actual translocation 
event. However, it remains unclear whether TatA does so by forming the pore-like 
structures that it displays when purified to homogeneity (Panahandeh et al., 2009). The 
energy for the process is derived from PMF. The Sec and the Tat pathways have not 
been characterized in S. aureus. Nevertheless, components of the two pathways have been 
identified based on BLAST searches with the corresponding proteins of Bacillus subtilis 
(Sibbald et al., 2006).  
1.3 Type I signal peptidases in bacteria  
1.3.1 Commonalities and differences among SPases of Gram-positive and 
Gram-negative bacteria 
The type I signal peptidases (EC 3.4.21.89) belong to the serine protease family S26 and 
are classified into the evolutionary clan of serine proteases SF, which utilize a Ser/Lys 
(prokaryotes) or possibly Ser/His (eukaryotes) catalytic dyad mechanism instead of the 
more common Ser/His/Asp triad mechanism (Paetzel et al., 2000). SPasesI are further 
subdivided into prokaryotic (P)-type and endoplasmic reticulum (ER)-type SPases. Apart 
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from other differences, the ER-type SPases have a histidine residue instead of the 
catalytic lysine in P-type SPases. All eubacterial SPases are of the P-type with the 
exception of B. subtilis, having both the (ER)-type (SipW) and the P-type (SipS, SipT, 
SipU, SipV) SPases (van Roosmalen et al., 2004). SPasesI from different bacterial species 
have five conserved regions denoted as boxes A-E as revealed by sequence alignment 
data (Paetzel et al., 2000). Although the Gram-positive and Gram-negative bacterial 
SPases have the same function, they do display the following differences. (i) Gram-
negative bacteria typically have only one SPaseI. For example E. coli has a single gene 
encoding SPaseI (lepB). This gene has been shown to be essential for cell growth and 
viability (Dalbey & Wickner, 1985). Gram-positive bacteria often have more than one 
SPaseI, of which none of the individual enzymes was found to be essential for viability. 
When a species contains multiple SPasesI, some seem to be more important for efficient 
preprotein processing than others. Therefore, they are grouped as major and minor 
SPases, respectively (van Roosmalen et al., 2004). In such cases, the SPases have 
overlapping but non-identical substrate specificities and some of the SPase-encoding 
genes are temporally regulated. (ii) Gram-negative and Gram-positive bacterial SPases 
differ in membrane topology in that the former typically are anchored in the cytoplasmic 
membrane by at least two N-terminal transmembrane segments while the latter usually 
have one N-terminal domain. For example, E. coli LepB has two N-terminal 
transmembrane segments, a small cytoplasmic domain between them and a large C-
terminal catalytic domain while e.g., S. aureus SpsB is predicted to have only one. (iii) The 
SPases of Gram-negatives are generally larger in size than those of Gram-positives 
mostly due to the presence of more than one N-terminal transmembrane segment (van 
Roosmalen et al., 2004). E. coli LepB and S. aureus SpsB contain approximately 300 and 
200 amino acids, respectively. (iv) The catalytic domain of SPasesI of most Gram-
positive bacteria is also significantly smaller compared to that of E. coli LepB, mainly due 
to the absence of a large β-sheet between the conserved domains D and E and a 
relatively small β–hairpin between domains B and C. (v) The SPases from the two groups 
also differ in their substrate specificities. For example, although active, none of the B. 
subtilis SPases were able to complement LepB-deficient E. coli cells for growth and 
viability (van Roosmalen et al., 2004). 
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It should be noted that in entire text that follows the terms ‘SPase(s)I’ or simply 
‘SPase(s)’ refers to the type I signal peptidase(s) only and LepB is used to refer to the 
SPaseI of E. coli. 
1.3.2 Biochemical characteristics  
Biochemical data of the type I SPases have been obtained largely from the Gram-
negative bacterium E. coli followed by the Gram-positive organisms Bacillus 
subtilis, Streptomyces lividans, Streptococcus pneumoniae (van Roosmalen et al., 2004). Based on 
the in vitro data available, the SPases of Gram-positive and Gram-negative bacteria have 
several properties in common which include (i) intermolecular self-cleavage of the 
enzyme; (ii) enhanced activity in the presence of some non-ionic detergents and 
phospholipids; (iii) reduced activity of the truncated SPases (devoid of the 
transmembrane segment) compared to the full-length SPases; (iv) high optimum pH 
(ranging from pH 8 to pH 11) in contrast to all other serine protease families. 
 
In vitro SPaseI assays involving preprotein or synthetic peptide substrates have been 
instrumental in characterization, enabling comparison between the SPases from different 
bacteria (Paetzel et al., 2000). One of the best SPase substrates for E. coli LepB is a full-
length hybrid preprotein substrate, pro-OmpA nuclease A which has S. aureus nuclease A 
attached to the signal peptide of the E. coli outer membrane protein, OmpA (Chatterjee et 
al., 1995). Using this substrate, the activation energy of LepB was estimated to be 10.4 ± 
1.6 kcal/mol, which indicates that this SPase is catalytically equally efficient as typical 
serine proteases with a Ser/His/Asp triad mechanism (Suciu et al., 1997). Synthetic 
peptide substrates in general are poor substrates, when compared to the full-length 
preproteins possibly due to conformational preferences for the latter which are not 
fulfilled by synthetic peptides (Dalbey et al., 1997). Despite this fact, a number of 
synthetic peptide substrates (Table 1.1) have proved indispensable for rapid screening of 
SPase inhibitors. 
 
It was observed early on that the bacterial type I signal peptidases are not inhibited by the 
standard protease inhibitors against the four standard protease classes (serine protease, 
cysteine protease, aspartic protease and metalloproteases) (Black et al., 1992; Kuo et al., 
1993; Zwizinski et al., 1981) and probably belong to a new protease family. The initial 
evidences for the SPases utilizing an unconventional Ser/Lys dyad mechanism came 
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Table 1.1: Comparison of the specific enzymatic activity of SPases for different peptide substrates used in 
screening assays of inhibitors and a preprotein substrate (topmost).   
Substrate (Reference) Assay                kcat/KM (M-1s-1) 
  S. aureus 
SpsB 
E. coli 
lepB 
S. pneumoniae 
Spi 
Pro-OmpA-Nuclease A  
(Chatterjee et al., 1995) 
SDS-PAGE/ 
densitometry 
16 1.1x107 - 
 
Y(NO2)FSASALAKIK(Abz) 
(Zhong & Benkovic, 1998) 
+FRET/ 
spectrofluorometry 
18.4 71.1 - 
 
K(5)-L(10)- Y(NO2)FSASALAKIK(Abz) 
(Stein et al., 2000) 
+FRET/ 
spectrofluorometry 
- 2.5x106 - 
 
KLTFGTVK(Abz)PVQAIAGY(NO2)EWL 
(Peng et al., 2001b) 
+FRET/ 
spectrofluorometry 
- - 2.7x102 
 
A proprietary lipopeptide substrate  
(Ashman et al., 2000) 
+FRET/ 
spectrofluorometry  
4.6x104 - - 
 
Decanoyl-LTPTAKAASKIDD-OH 
(Bruton et al., 2003) 
+FRET/ 
spectrofluorometry 
2.3x106 4.2x105 - 
 
Fusion protein made up of signal peptide of outermembrane protein A from E. coli and the nuclease A from S. 
aureus. 
Fluorescence resonance energy transfer 
from site-directed mutagenesis (Sung & Dalbey, 1992; Tschantz et al., 1993) and chemical 
modification studies on E. coli LepB (Black et al., 1992; Black, 1993; Paetzel et al., 1997), 
Bacillus subtilis SipS (van Dijl et al., 1995), S. pneumoniae Spi (Peng et al., 2001a) and was 
finally confirmed by the crystal structure of LepB.  
 
1.3.3 Structural data 
For structure determination, a truncated derivative of E. coli LepB (referred to as 2-75 
SPase) lacking residues from 2-75 corresponding to the N-terminal transmembrane 
regions (MW of 27.9 kDa; MW of full-length = 35.9 kDa) was designed, in order to 
avoid problems of instability due to self-cleavage and to improve solubility. The 2-75 
SPase has been purified, characterized (Kuo et al., 1993; Tschantz et al., 1995), crystallized 
in its apoform (Paetzel et al., 1995; Paetzel et al., 2002a) and in complex with different 
types of inhibitors [β-lactam (Paetzel et al., 1998), lipopeptide (Paetzel et al., 2004), 
lipopeptide and a β-sultam inhibitor (Luo et al., 2009)] and has also been used in nuclear 
magnetic resonance (NMR) studies (Musial-Siwek et al., 2008b). Nevertheless, this mutant 
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UFigure 1.3 U: A ribbon diagram of the general fold 
of truncated E. coli LepB (2-75). The conserved 
domain I β-sheet is in green and the domain II β-
sheet is in blue. The β-hairpin extension protruding 
from domain I is in purple. Active site residues Ser 
and Lys are labelled 90 and 145 respectively 
[reprinted by permission from Macmillan 
Publishers Ltd: Nature (Paetzel et al., 1998)], 
copyright (1998)]. 
also required the non-ionic detergent Triton X-100 for optimal activity and crystallization 
and the addition of SPase inhibitor greatly facilitated in obtaining high-resolution 
structural data. Interestingly, an NMR study was reported on the full-length SPase 
(Musial-Siwek et al., 2008a).   
1.3.3.1 3D structure of the catalytic domain of E. coli SPase, LepB 
The structure of 2-75 SPase 
(Paetzel et al., 1998) has a primarily β-
sheet protein fold consisting of two 
anti-parallel β-sheet domains (termed 
Domain I and II), two small 310-
helices (residues 246-250 and 315-
319; see Figure 1.3) and one small α-
helix (residues 280-285). Domain I, 
termed the “catalytic core”, contains 
the conserved regions (Boxes B-E), 
all of which reside near or are a part 
of the active site (Paetzel et al., 2000). 
The structure has four extended 
loops or hairpins that are disordered 
(108-124, 170-176, 198-202, and 304-
313). The large β-sheet Domain II 
(154-264) and a long extended β-
ribbon (107-122) observed in E. coli 
SPase structure are insertions within Domain I. Structure-based multiple sequence 
alignment data of representative type I SPases reveal that Domain I is conserved 
throughout evolution. In contrast, Domain II is relatively smaller and the extended β-
ribbon is lacking in Gram-positive bacterial SPases which is attributed to the generally 
smaller size of these SPases (Paetzel et al., 2000). The conserved Domain I also contains a 
large unusually exposed hydrophobic surface, which is rarely found in soluble proteins. 
This hydrophobic surface runs along the β-sheet made up from three β-strands and is 
proposed to be involved in membrane association (Paetzel et al., 1998). Notably, one of 
the β-strands has an essential Trp300 (Kim et al., 1995) which, like other aromatic amino 
acids, is thought to play an important role in protein/membrane interfaces. This residue 
Chapter 1 
10 
is presumed to facilitate the insertion or association of E. coli SPase into the membrane 
(Paetzel et al., 2000). Sequence alignments indicate that several conserved aromatic or 
hydrophobic residues exist in the proposed membrane-association domain in both 
Gram-positive and Gram-negative bacterial type I SPases (Paetzel et al., 2000). The recent 
crystal structure of 2-75 SPase revealed the presence of pronounced solvent channels 
directly adjacent to the proposed hydrophobic membrane-association domain where the 
required detergent is likely to accumulate, stabilizing the significantly exposed 
hydrophobic surface area on the E. coli signal peptidase molecule (Luo et al., 2009).  
 
The structural motifs of the enzyme residing in the four conserved boxes could be 
identified in the tertiary structure (Paetzel et al., 2000). Box B (residues 88-95) contains 
the proposed nucleophile Ser90 that resides on a well-ordered loop (see Figure 1.3; 
shown in red) between the first two β-strands of the periplasmic catalytic portion of E. 
coli LepB. Box B also contains Ser88 which is conserved in SPases of Gram-negative 
bacteria (replaced by Gly in SPases of Gram-positive bacteria) and Met91, which allows 
for the placement of its sulphur side-chain adjacent to the nucleophile serine, in common 
with that observed in the active site of other serine proteases (Paetzel et al., 2000). Boxes 
C (residues 127-134) and D (residues 142-153) contain two antiparallel hydrogen-bonded 
β-strands (β-5 and β-6) of which the latter contains the proposed general base Lys145 
and has main chain atoms aligned perfectly to make β-strand-type hydrogen bonds with 
the signal peptide substrate, also in common with other serine proteases. Box E contains 
the strictly conserved Gly272 explained by the fact that it sits directly adjacent to the Nζ 
of Lys145 and any other residue at this site would necessarily position a side chain into 
this region that would clash with the essential Lys145 side chain. Box E also contains a 
conserved Ser278, which hydrogen bonds to the Lys145 and is suggested to help position 
the Lys145 Nζ for its general base role with Ser90. The highly conserved Asp280 and 
Arg282 form a strong salt bridge and play an indirect role in catalysis by contributing to 
the structural stabilization of the active site.  
1.3.4 Catalytic residues  
The first direct evidence that the Ser90 Oγ acts as the acylating nucleophile in the SPase 
hydrolysis reaction came from the co-crystal structure of 2-75 SPase with 5S,6S β-
lactam (penem) inhibitor (Paetzel et al., 1998). The electron density at the active site 
revealed a covalent bond between the Ser90 Oγ and the carbonyl (C7) of the inhibitor. 
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The SPase-inhibitor co-crystal structure also showed that the Ser90 O γattacks the si-face 
of the β-lactam amide bond, a peptide-bond analogue. This indicates that SPasesI are 
unique and differ from all known Ser/His/Asp serine proteases and the group 2b β-
lactamases, which perform a re-face attack. These observations further supported the 
earlier prediction of si-face attack based on the preference of SPasesI for 5S rather than 
the 5R stereochemistry of the penem inhibitor (Allsop et al., 1997). Further, the structure 
revealed that Nζ of Lys145 forms a strong hydrogen bond with Ser90 Oγ and is the only 
titratable group in the vicinity of the active-site nucleophile. The position of Lys145 Nζ is 
fixed relative to Ser90 by hydrogen bonds to the conserved Ser278 Oγ and the carbonyl 
oxygen (O10) of the inhibitor side chain. Therefore, Lys145 is correctly positioned to act 
as the general base in both the acylation and deacylation step of catalysis. The side chain 
of Lys145 is completely buried in the inhibitor complex, making van der Waals contacts 
with the side-chain atoms of Tyr143, Phe133 and Met270 and the main chain-atoms of 
Met270, Met271, Gly272 and Ala279, all of which are contained within the catalytic core 
(Domain I). The hydrophobic 
environment surrounding the Lys145 ε–
amino group is likely essential for 
lowering its pKa, such that it can reside 
in the deprotonated state required for 
its role as the general base (Paetzel et al., 
1998). An important component of the 
catalytic machinery in serine proteases is 
the oxyanion hole that works by 
neutralizing the developing negative 
charge on the scissile carbonyl oxygen 
during the formation of the tetrahedral 
intermediates. The co-crystal structure 
with penem first indicated that Ser90 
amide might contribute to the 
formation of an ‘oxyanion hole’ as the 
main-chain amide of Ser 90 forms a 
strong hydrogen bond with the carbonyl 
oxygen (O8) of the cleaved β-lactam ring. Subsequent mutagenesis data (Carlos et al., 
2000a) and analysis of the active site of the apoenzyme (Paetzel et al., 2002a) suggested 
 
UFigure 1.4 U: The three conserved water 
molecules in the active site of E. coli SPase. 
The residues near the active site and binding 
cleft are represented in stick and coloured by 
element (carbon, green; nitrogen, blue; 
oxygen, red). The hydrogen bonding 
interactions between the waters (cyan 
spheres) and the residues of SPase I are 
indicated in red dashed lines [reprinted with 
permission from Luo et al., 2009. Copyright 
2009 American Chemical Society]. 
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that the other contributor to the oxyanion hole could be side-chain hydroxyl hydrogen 
(Ser88 OγH) besides the main-chain amide hydrogen (Ser90 NH). Gram-negative 
bacterial SPases are unusual in this respect as the oxyanion hole is typically formed by 
two main-chain amide hydrogens that serve as hydrogen bond donors to the developing 
oxyanion (Menard & Storer, 1992). However, in most SPases of Gram-positive bacterial 
origin Ser88 is replaced by a Gly residue and it is assumed that the main chain NH of the 
Gly might contribute in stabilization of the oxyanion transition state (van Roosmalen et 
al., 2004). A comparison of the apoenzyme structure (Paetzel et al., 2002a) with the 
previously obtained acyl-enzyme structure showed significant side-chain and main-chain 
differences in the binding site and active site regions, which resulted in a smaller S1 
binding pocket in the apoenzyme. The apoenzyme structure also revealed three 
conserved water molecules near the active site designated as water 1, water 2 and water 3 
(Figure 1.4). Water 1 is coordinated to Met91 backbone NH, Ser88 O and Leu95 O. 
Water 2 is coordinated to Ile144 NH. Water 3 is coordinated to the Nζ of Lys145 and is 
hypothesized to function as the deacylating (also called the “catalytic”, “hydrolytic” or 
“nucleophilic”) water in the SPaseI catalysis. A homology model of Gram-positive 
Bacillus subtilis SipS and supporting data have been used to compare the possible role of 
corresponding residues in catalysis, which ultimately will have to be confirmed when the 
crystal structure becomes available (van Roosmalen et al., 2004). 
1.3.5 Substrate specificity 
 
Mapping of surface clefts on the SPase structure and modelling of a tetrapeptide (poly-
Ala) into the active site led to the identification of two shallow hydrophobic pockets 
(designated as S1 and S3 substrate binding sites) appropriate for accommodating -1 (P1) 
and -3 (P3) residues of the signal peptide (Paetzel et al., 2000). The model helped explain 
the Ala-X-Ala (or -3,-1 rule) cleavage-site specificity of signal peptidases.  Furthermore, 
modelling of an E. coli periplasmic dithiol oxidase, DsbA 13-25 precursor protein into the 
active site of E. coli LepB led to defining thirteen subsites S7 to S6’ within the SPase 
substrate-binding site (Choo et al., 2008). It has been suggested that the narrow clefts at 
S3, S2, S1 and S1’ play a direct role in high specificity of the signal peptide residues while 
the larger clefts at S3’ and S4’ could be responsible for interactions with the mature 
moieties (Figure 1.5). Additionally, NMR studies on the 2-75 SPase revealed that a 
small subset of eighteen residues, mostly residing in the proposed binding pockets, 
undergo a conformational change upon (synthetic alkaline phosphatase) signal peptide 
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UFigure 1.5 U: E. coli SPase substrate-binding site. The top view of the molecular surface of the 
SPase binding site (coloured blue) with Cα trace of the SPase (blue lines). The pockets 
accommodating signal peptide side chains are shown in detail in the surrounding views and 
numbered according to their position along the peptide from the S1 pocket containing the 
nucleophile Ser90 [reproduced from (Choo et al., 2008) under CCL]. 
binding, while the rest of the enzyme structure did not change substantially (Musial-
Siwek et al., 2008b). The residues whose conformation changes upon signal peptide 
binding include the catalytic residues (Ser90 and Lys145) and residues contributing to 
SPase cleavage fidelity and substrate specificity (Ile86 and Ile144) (Ekici et al., 2007; Karla 
et al., 2005).  The NMR data suggest that residues of S1 and S3 have to reorient in order 
to achieve close complementation with the docked -1 and -3 signal peptide residues, 
consistent with an induced fit hypothesis. Despite the conformational alterations which 
are ideally suited for accommodating signal peptide cleavage regions with a spectrum of 
different sequences, the region is too small to accommodate large side chains (Musial-
Siwek et al., 2008b). The residues contributing to the S1 substrate binding pocket are 
primarily hydrophobic and include UIle86 U, Pro87, USer88 U, USer90 U, UMer91U, ULeu95U, UIle144U, 
Tyr143 and ULys145U (Choo et al., 2008; Paetzel et al., 2000). The residues perturbed in the 
NMR study (Musial-Siwek et al., 2008b) are underlined. It must be noted that Pro87 was 
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not identified by NMR since Pro residues do not have NH-CaH correlations. In addition, 
one other residue remained unidentified in NMR, which Musial-Siwek and co-workers 
(2008b), believe to be Phe84 or Tyr143. The S2 subsite, which comprises residues UGln85U, 
UIle86U, Pro87, USer88U, UMet91 U and UIle144U, constitutes the deepest cavity within the substrate 
binding site and largely overlaps with S1 due to a pronounced backbone twist in the P3 
to P1’ binding conformation of the precursor protein. Notably, the modelling studies by 
Choo and co-workers (2008) showed that the P2 side chain is not solvent-exposed as 
believed earlier (Paetzel et al., 2000), but is completely buried at this location (S2) due to 
the twist in the P3 to P1’ binding conformation which is in agreement with recent data 
(Luo et al., 2009). This pocket can accommodate residues with large side chains and 
appears to play an important role in substrate specificity of E. coli type I SPase. The S3 
subsite, also predominantly hydrophobic in nature, is composed of non-polar atoms 
from residues Phe84, UGln85U, UIle86U, Pro87, UIle101U, UVal132 U, UIle144U and Cβ of UAsp142U and 
is located diagonally across from the S1 site (Choo et al., 2008). The S3 pocket constitutes 
the third deepest cavity and can accommodate a wide variety of side chains consistent 
with the observation that larger residues can occur at the P3 (-3) than at the P1 (-1) 
position of the substrate (Nielsen et al., 1997). The S4 subsite consists of Phe84, UGln85 U, 
Pro87 and UAsp142U, which are in contact with P4 of the substrate. Collectively, the 
modelling data by Choo and co-workers (2008) showed that the bound precursor protein 
makes significant contact with E. coli LepB from S7 to S6’. More importantly, the side 
chains of P1’ to P5’ residues of the mature moiety are in position to make significant 
contacts with E. coli LepB, implying that both signal and mature moiety sequences play a 
direct role in catalysis. The NMR data also showed the involvement of three additional 
residues Ile80, Glu82 (residing in the S7 pocket proposed by Choo and co-workers, 
2008) and Gly109 that suggests interaction of the SPase with the C-terminus of the 
hydrophobic core region of the peptide.  
 
In addition, an analysis of the side chain orientation in the P3-P1’ segment of the 
preprotein in the active site region the SPase showed the pattern ↓↓↓· (where ↓ 
represents a side chain oriented towards the binding site and · represents a side chain 
oriented away or across the binding site) supporting the stringent selectivity criteria in the 
P3, P2 and P1 regions and the observed variability in P1’ (Choo et al., 2008).  
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UFigure 1.6 U: Proposed catalytic mechanism of bacterial SPasesI. The reaction proceeds through an 
oxyanion tetrahedral intermediate followed by the loss of the mature domain of the substrate, 
resulting in an acyl-signal peptide enzyme intermediate. The acyl-enzyme intermediate is attacked 
by a water molecule, releasing the cleaved signal peptide and the free enzyme [reprinted with 
permission from Paetzel et al., 2002b. Copyright 2002 American Chemical Society]. 
1.3.6 Proposed mechanism of catalysis 
A mechanism of catalysis for preprotein cleavage by E. coli LepB was proposed based on 
the crystal structure, modelling and other biochemical data (Paetzel et al., 2000) and is in 
agreement with currently available data. First, the signal peptide binds to the SPase with 
the P1 to P4 residues in an extended β-conformation, forming hydrogen bonds with the 
β-strand containing Lys145 (Fig. 1.6). The residues P1 and P3 of the substrate reside in 
the hydrophobic S1 and S3 substrate-binding pockets. Upon binding of the preprotein 
substrate, the neutral Lys145 ε-amino group, oriented by the Oγ Ser278 abstracts a 
proton from the side-chain hydroxyl of Ser90, activating the Ser90 Oγ  for nucleophilic 
attack on the carbonyl (si-face) of the scissile peptide bond (i.e. the SPase cleavage site). A 
tetrahedral intermediate is formed which is electrostatically stabilized by hydrogen bonds 
to the oxyanion hole, formed by the Ser90 main-chain amide and the Ser88 side-chain 
hydroxyl group. Next, the ammonium group from the side chain of Lys145 would then 
donate a proton to the leaving group amide (i.e. the N-terminus of the mature protein). 
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This releases the mature protein from the SPase and a signal peptide-bound acyl-enzyme 
intermediate is formed. The deacylating water then loses its proton to the Lys145 general 
base and the hydroxyl group attacks the ester carbonyl to produce another tetrahedral 
intermediate. This then breaks down to release the signal peptide, regenerating the SPase 
active site. 
 
1.4 The type I signal peptidases as drug targets 
Type I signal peptidases were proposed as novel antibiotic targets (Black & Bruton, 1998; 
Paetzel et al., 2000) as they fulfill certain basic criteria. Firstly, SPasesI are ubiquitous in all 
bacteria with the exception of Mycoplasma genitalium (Dalbey et al., 1997; Fraser et al., 
1995). However, it is interesting to note that in the related organism M. pneumoniae, 
SPaseI-like activity has been demonstrated despite the absence of a gene encoding SPaseI 
(Catrein et al., 2005). Secondly, SPaseI activity is essential for cell viability (Dalbey & 
Wickner, 1985; Date, 1983) as inhibition of SPaseI activity leads to accumulation of 
secretory proteins in the cell membrane and eventual cell death (Koshland et al., 1982). 
Temperature-sensitive E. coli strains IT89/IT41 (Inada et al., 1989) with an amber 
mutation in the lepB gene (Cregg et al., 1996), show accumulation of preproteins and 
reduced growth rate at the nonpermissive temperature of 42 °C. These temperature-
sensitive mutant strains have been used to confirm the essential function of SPases from 
several bacteria including human pathogens such as Staphylocccus aureus (Cregg et al., 1996), 
S. epidermidis (Bockstael et al., 2009b), Streptococcus pneumoniae (Zhang et al., 1997), Salmonella 
Typhimurium (van Dijl et al., 1990), Legionella pneumophila (Lammertyn et al., 2004), 
Rickettsia rickettsii and R. typhi (Rahman et al., 2003). Thirdly, targeting the bacterial SPasesI 
is likely to limit toxicity to humans due to the differences in structure, localisation and 
possibly catalytic mechanism from that of the eukaryotic SPases. The bacterial SPases are 
believed to be monomeric, located at the cytoplasmic membrane surface with their active 
site on the outer leaflet making it relatively accessible to potential inhibitors and operate 
by a Ser-Lys catalytic dyad mechanism. The eukaryotic SPases are multimeric, and have 
their active-site region located in the mitochondrial inner-membrane space 
(mitochondrial Imp1 and Imp2 SPases) or in the ER lumen (ER signal peptidase 
complex). In the latter case, Lys is not used as a general base (Paetzel et al., 2002b). 
Further, the si-face attack of the substrate scissile amide carbonyl by the SPasesI, rather 
than the re-face observed in all serine-dependent hydrolases, also enables selective 
Introduction 
 17
inhibition. Additionally, targeting the SPases debilitates certain bacterial defences, 
increases susceptibility to antibiotics and potentially facilitates clearance by the human 
immune system. For instance, in the food-borne pathogen Listeria monocytogenes, deletion 
of one of the three SPase-encoding genes, sipZ, impaired secretion of the virulence 
factors such as listeriolysin O and phospholipase C and rendered it almost avirulent 
(Bonnemain et al., 2004). A few examples of SPase I-dependent proteins important in this 
respect are: β-lactamases that confer resistance to β-lactam antibiotics, pertussis toxin 
from Bordetella pertussis, HMW1 adhesin of Haemophilus influenzae, pyelonephritis-
associated pili (Pap) important for pathogenesis in uropathogenic E. coli strains and IgA 
protease from Neisseria gonorrhoeae.  
 
1.5 Inhibitors of the type I SPases and their antibacterial activity 
As mentioned earlier, SPasesI are resistant to general protease inhibitors. On the other 
hand apparently, very few SPase molecules per cell need to be fully active for E. coli cells 
to divide and grow, at least at 30 °C in a non-stressed environment (Cregg et al., 1996). 
Therefore finding potent SPase inhibitors with effective antibacterial activities is 
considered a challenging task. Initial studies showed that E. coli LepB activity is adversely 
affected by high concentration of sodium chloride (> 160 mM), magnesium chloride (1 
mM) and dinitrophenol (Zwizinski et al., 1981) and since then, a few effective inhibitors 
have been identified as described below.  
1.5.1 Peptide and protein inhibitors 
The studies involving this type of inhibitors were the first to provide substantial basic 
information about the SPasesI. For example, in vitro inhibition of the cleavage of M13 
procoat and maltose binding protein (MBP) in the presence of a synthetic leader peptide 
comprising of 23 residues preceding the M13 bacteriophage procoat-cleavage site 
demonstrated that signal peptides could competitively inhibit SPaseI and that leader 
peptide is indeed the primary region of substrate recognition by the signal peptidase 
(Wickner et al., 1987). Preproteins or synthetic peptide substrates with Pro at +1 position 
(the first residue in the mature part of the protein) remain uncleaved and competitively 
inhibit the activity of E coli LepB in vivo, rendering an impaired growth to the cells 
(Barkocy-Gallagher & Bassford, 1992; Nilsson & von Heijne, 1992). This feature is also 
common with proteases in general as they are unable to cleave an X-Pro bond. However, 
attempts to find effective peptide inhibitors using the classical approach were not 
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successful until the approach was applied to lipopeptide inhibitors. Interestingly, an 
antimicrobial peptide derivative of flesh fruit fly resembling a natural signal sequence was 
found to competitively inhibit SPaseI (Kaderbhai et al., 2008). The protease-resistant 
peptide (D)-KLKL6KLK has an IC50 of 50 µM against LepB and MIC of 16 µM against 
E. coli with bactericidal activity also against Gram-positive pathogens (Table 1.2).  
1.5.2 β-lactam type inhibitors 
The β-lactam analogs, monocyclic azetidinones, were the first (but not very potent) non-
peptide inhibitors reported to inhibit E. coli LepB in a pH- and time-dependent manner 
(Kuo et al., 1993). 5S penem stereoisomers were the first potent irreversible inhibitors 
identified along with a few other weak inhibitors including clavam and clavem systems 
(Black & Bruton, 1998). The compound allyl (5S,6S)-6-[(R)-acetoxyethyl] penem-3-
carboxylate (Figure 1.7) inhibits SPaseI activity of both E. coli LepB (IC50=0.38 µM) and 
S. aureus SpsB, completely blocks the processing of β-lactamase protein by the leader 
peptidase of an E. coli ESS strain which has a leaky outer membrane (Black & Bruton, 
1998) and was also used for co-crystallization of the 2-75 SPase (Paetzel et al., 1998). 
The co-crystal structure revealed that the side-chain methyl group (C16) of the penem, 
previously reported to be essential for the 
effectiveness of the inhibitor, was located in 
the SPase substrate-binding pocket (S1), 
probably mimicking the P1 (-1) (Ala) side 
chain of the substrate. In addition the co-
crystal structure also showed that the inhibitor 
acts via acylation of the active-site serine. 
Unfortunately, penem inhibitors have poor 
antibacterial activity against some of the 
clinically more relevant strains, which might be 
explained by low compound penetration 
across the bacterial wall and compound 
instability. Recently, the synthesis of the 5S- 
penem was described and as with the parent penem, no significant antibacterial activity 
was observed against S. aureus and E. coli. Interestingly moderate activity was observed 
against S epidermidis (Harris et al., 2009). In addition, carbamate-derivatized penems 
moderately inhibited MRSA (Table 1.2).  
UFigure 1.7 U: Structure of (5S,6S)-6-
[(R)acetoxyeth-2-yl]-penem-3-
carboxylatepropane [PDB ID: 1PN 
(Paetzel et al., 1998)] 
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UFigure 1.8 U: Structures of arylomycin A2 and 
lipoglycopeptide inhibitors of the SPasesI [reprinted with 
permission from Roberts et al., 2007. Copyright 2007 
American Chemical Society]. 
 
Furthermore, (5S)-tricyclic penems with a third heterocyclic ring fused to the C2 and C3 
positions of the (5S,6S)-6-[(R)-hydroxyethyl]-penem core have an increased potency with 
IC50 values of 0.2 µM and 5 µM against E. coli and methicillin-resistant Staphylococcus aureus 
(MRSA) SPases, respectively (Hu et al., 2003). This higher in vitro potency is predicted to 
be likely due to additional binding features, as observed by molecular modelling. In these 
studies, tricyclic penem was found to extend into the S3-binding pocket of the SPase. 
Again, the antibacterial activity of the tricyclic penems on whole cells was poor, possibly 
because of instability of the compound.  
1.5.3 Natural and synthetic lipopeptides (arylomycins) and 
lipoglycopeptide inhibitors  
Arylomycins A and B were identified as new biaryl-bridged lipopeptide antibiotics 
produced by Streptomyces sp. Tü 6075 (Schimana et al., 2002) and classified as secondary 
metabolites synthesized by non-ribosomal peptide synthesis. Their antibiotic property 
was subsequently attributed to their ability to inhibit SPasesI. Arylomycins are 
lipohexapeptides with the sequence D-N-MeSer-D-Ala-Gly-L-N-MeHpg-L-Ala-L-Tyr, 
cyclised by a [3,3] biaryl bond between MeHpg and Tyr (in the colourless arylomycin A, 
or a nitro-substituted Tyr in the yellow-coloured arylomycin B series) and with a C11-15 
branched fatty acid attached via an amide bond to the amino terminus (Holtzel et al., 
2002). Molecules belonging to the arylomycin B series have significantly higher 
antibacterial activities compared 
to arylomycins of the A series 
suggesting that the nitro 
substitution and the length of 
the fatty-acid side chain 
influences the activity 
(Schimana et al., 2002). 
 
Arylomycin A2 (Figure 1.8) 
binds non-covalently to the 
active site of E. coli SPase in a 
two-step binding mechanism as revealed by the co-crystal structure (Paetzel et al., 2004). 
The structure shows the COOH-terminal biaryl-bridged end of the inhibitor pointing to 
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the active site and making parallel β-sheet interactions with the two β-strands lining the 
SPase-binding site. Further, the carboxylate oxygen atom (O45) of arylomycin A2 
positions in the active site such that it makes hydrogen bond interactions with each of 
the catalytic residues of LepB: the nucleophile Ser90, the general base Lys145 and the 
oxyanion hole Ser88. The L-Ala methyl side chain (C30) of arylomycin A2 sits in the 
proposed S3-binding pocket and the 
D-Ala methyl side chain of the 
inhibitor points to a shallow pocket 
that might represent the S5-binding 
pocket of the enzyme. Interestingly, 
the recent structure of 2-75 SPase in 
ternary complex with arylomycin A2 
and a morpholino-β-sultam derivative 
(BAL0019193) revealed SPase 
inhibition by the two compounds at 
the same time via binding to non-
overlapping subsites near the catalytic 
center (Luo et al., 2009). The ternary 
structure provides a detailed 
structural information on the binding 
mode of arylomycin A2, with electron 
density for the complete arylomycin 
A2 including the 12-carbon fatty acid 
of arylomycin. The latter observation is in agreement with the accumulating evidence that 
the fatty acid chain is important for effective SPase inhibitors / synthetic substrates, as 
discussed later. The methylene groups of fatty acid make van der Waals interactions with 
part of a large hydrophobic surface with in the region of the predicted membrane-
association surface of the SPase. β-Sultams are reactive sulfonyl analogues of β-lactams 
that inactivate serine enzymes by sulfonylation of the active-site Ser (Page, 2004). 
Remarkably, the β-sultam inhibitor in the ternary complex with SPase was bound non-
covalently above the active site of the SPase, taking a parallel orientation relative to the 
biaryl ring moiety of arylomycin A2. The β-sultam inhibitor possibly acts by displacing a 
water molecule that is coordinated to the catalytic Lys145, proposed to function as the 
deacylating water in catalysis. This mechanism of inhibition is different from the action 
 
UFigure 1.9 U: Overall binding theme of arylomycin 
A2 and BAL0019193 inhibitors. SPase I is in ribbon 
representation (green). Inhibitor arylomycin A2 is 
represented as stick and coloured by element 
(Carbon, yellow; nitrogen, blue; oxygen, red). 
Inhibitor BAL0019193 is represented as a stick and 
coloured by element (carbon, cyan; nitrogen, blue; 
oxygen, red) [reprinted with permission from Luo 
et al., 2009. Copyright 2009 American Chemical 
Society]. 
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mechanism used by β-sultams to inhibit β-lactamases and D,D-peptidases, which also use 
Ser/Lys catalytic activation (Luo et al., 2009). The structural data showing that SPase can 
be inhibited by two separate inhibitors at the same time (Figure 1.9), provide excellent 
possibilities for rational drug design.   
 
Lipoglycopeptides are a group of natural compounds that inhibit SPaseI, isolated from 
Streptomyces spp., (Kulanthaivel et al., 2004). Also classified as secondary metabolites, these 
lipoglycopeptides share the core structural features of arylomycins but contain a 2-
deoxymannose sugar unit in the macrocycle and have a longer (up to five carbon) fatty- 
acid tail (Figure 1.8).  These compounds are potent inhibitors of SPases of E. coli and S. 
pneumoniae with modest antibacterial activity against a panel of pathogens (see Table 1.2). 
The compounds also block the protein secretion in whole cells as demonstrated by the 
inhibition of β-lactamase release from S. aureus. It was observed that the 
lipoglycopeptides as well as the β-lactam inhibitor 5S,6S-penem are more potent against 
the Gram-negative E. coli SPase than the Gram-positive S. pneumoniae SPase, possibly 
reflecting on difference in the structure of these enzymes (Kulanthaivel et al., 2004). In 
addition, while a good correlation exists between IC50 and MIC values in S. pneumoniae, 
the MIC values were much higher (with respect to the IC50) in E. coli and H. influenzae, 
possibly due to the additional outer membrane barrier that is present in Gram-negative 
bacteria. 
 
Furthermore, the synthesis of arylomycin A2 was reported along with the effect imparted 
by the three main modifications: N-methylation, glycosylation and lipidation (common to 
arylomycins and the related lipoglycopeptides) on biological activity (Roberts et al., 2007). 
The synthetic arylomycin A2 was found to inhibit the polymyxin B nonapeptide-
permeabilized E. coli strain MG 1655 at high concentrations (MIC of 128 µM) but had no 
effect on non-permeabilized cells. Roberts and co-workers (2007) observed that 
arylomycin A2 does not inhibit S. aureus (up to 128 µM) but remarkably it is highly potent 
against S. epidermidis (MIC of 1 µM). Additionally, it was observed that while glycosylation 
appeared less critical, fatty acid chain length and N-methylation influenced biological 
activity but varied depending on the species. Interestingly, Roberts et al., 2007, compared 
the biological activity of synthetic arylomycin A2 and its derivative with a longer fatty acid 
chain and found that the longer fatty acid chain increased biological activity on S. aureus. 
The antibacterial activity of arylomycin A2 was also extended to its possible use on S. 
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Table 1.2: Inhibitors of the bacterial type I signal peptidases with their in vitro and in vivo activities 
Inhibitor SPase IC50 Micro-organism MIC Reference 
Peptide 
1 (D)-KLKL6KLK-NH2 LepB 30 µM E. coli 
E. coli 
16 µM 
4.8 µM 
(Kaderbhai et 
al., 2008) 
   ND S. aureus 8 µM 
   ND H. influenzae >64 µM 
   ND S. pneumoniae 4.8 µM 
β-lactam type  
2 Allyl (5S,6S)-6-[(R)-
acetoxyethyl] penem-3-
carboxylate 
LepB 0.38 µM E .coli ND (Black & 
Bruton, 1998) 
3 (5S,6S)-6-[(R)-
hydroxyethyl] penem 
core with a C3 p-
nitrobenzyl protected 
carboxylic acid 
 ND E .coli ≥200 
µg/ml 
(Harris et al., 
2009) 
   ND S. aureus ≥200 
µg/ml 
   ND S. epidermidis 50 µg/ml 
4 Carbamate-derivatized 
penem  
 ND MRSA 100 µg/ml 
5 (5S)-tricyclic penem LepB 0.2 µM E. coli ND (Hu et al., 2003) 
  SpsB 5 µM S. aureus (MRSA) >128 
µg/ml 
Lipoglycopeptide 
6 Natural 
lipoglycopeptides 
LepB 0.11-0.19 
µM 
E. coli 4-8 µM (Kulanthaivel et 
al., 2004) 
  Spi 2.4-24.9 
µM 
S. pneumoniae 8-64 µM 
   ND S. aureus 32-64 µM 
   ND H. influenzae 64-64 µM 
Lipopeptide (natural/synthetic) 
7 Arylomycin A2  ND E. coli >128 µM (Roberts et al., 
2007) 
    E. coli 128 µM  
  SpsB (1 µM) S. aureus >128 µM  
  - ND S. epidermidis 1 µM  
Lipopeptide (rationally designed) 
8  Decanoyl-
LTPTAKAPSKIDD-
OH 
SpsB 0.6 µM S. aureus ND (Bruton et al., 
2003) 
9 Decanoyl-LTPTANA- 
α-ketoamide analogs 
SpsB 0.1-16 
µM 
S. aureus ND 
10 Decanoyl-PTANA-
aldehyde 
SpsB 0.09 µM S. aureus 125 µg/ml (Buzder-Lantos 
et al., 2009) 
  LepB 13.4 µM E. coli >500 
µg/ml 
ND, not determined. 
epidermidis biofilms as observed by a dose-dependent reduction in cell viability (Bockstael 
et al., 2009b).  
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1.5.4 Rationally designed lipopeptide inhibitors   
Compounds designed on the basis of preprotein sequence data in S. aureus, incorporating 
key structural features of a signal sequence namely a membrane anchor, a helix terminus 
or turn motif and the AXA cassette led to the identification of highly effective synthetic 
substrates and inhibitors of SpsB (Bruton et al., 2003). Bruton and co-workers (2003) 
confirmed that SpsB could be inhibited in a classical manner by either incorporation of a 
proline at P1’ or by introducing a serine trap (α-ketoamides) at the cleavage site of a 
lipopeptide substrate to obtain competitive or time-dependent inhibitors, respectively 
(Table 1.2). A competitive inhibitor described by Bruton co-workers (2003) was used as a 
lead compound to optimize the minimum length required for effective inhibition and to 
confirm that the fatty acid chain is essential for activity (Buzder-Lantos et al., 2009). 
Reducing the length of the core lipopeptide by eliminating amino acids from both 
termini and conversion of the peptide (with the C-terminal carboxylic acid) to an 
aldehyde resulted in an improved potency against SPases of S. aureus and E. coli (Table 
1.2).  On the other hand, the lipopeptide aldehyde had no significant antibacterial activity.  
 
The amino-terminal fatty acid in the inhibitor appears to be critical for both in vitro and in 
vivo activity against S. aureus SpsB and E. coli LepB. A direct association between the fatty 
acid with the SPase was also observed in the recent crystal structure of E. coli LepB (Luo 
et al., 2009). Additionally, previous attempts at developing peptide inhibitors using the 
classical approach were not effective, most likely due to the absence of the fatty acid. 
Although, the reason for this is still unclear, it is presumed that the amino-terminal fatty 
acid might aid in orientating the inhibitor/substrate appropriately in the binding cleft of 
the enzyme by mimicking the hydrophobic region of the signal peptide of preproteins. 
Another hypothesis is that the fatty acid in the inhibitor probably helps in partitioning 
into the hydrophobic part of the detergent milieu on which the signal peptidase is likely 
to be present as even the soluble derivatives are detergent-dependent. With regard to 
their potential use as drugs, however, this requirement might give them a slight 
disadvantage over small molecule inhibitors. 
 
In general, a lack of correlation between signal peptidase inhibition and MICs 
observed for different compounds on different bacterial cells has been observed, 
which is unlikely due to a single factor. The possible reasons for disparities in the 
biochemical and whole cell assays include (a) the problem of penetration of the 
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UFigure 1.10 U: Scanning electron 
micrograph (SEM) showing clumps of S. 
aureus at 50,000x magnification (Source: 
CDC, PHIL). 
compound in order to reach the target, (b) compound stability in vivo or modifications 
as a result of exposure to cellular enzymes and (c) the presence of an additional 
selective permeability barrier (the outer membrane) in Gram-negative bacteria which 
hinders accessibility to the target. In the case of lipopeptide aldehyde and arylomycin 
inhibitors, a high concentration of the compounds is needed to inhibit S. aureus in 
contrast to their high in vitro potency against SpsB. This suggests that additional 
factors such as those mentioned above (see a & b) also may play a role in a 
compounds biological activity. 
 
1.6 Staphylococcus aureus 
1.6.1 Microbiology 
Staphylococcus aureus belongs to the genus Staphylococci, comprising of Gram-positive, non-
spore forming, non-motile, catalase-positive, spherical bacteria of approximately 1 µM in 
diameter. Staphylococci appear as grape-like 
clusters when viewed under a microscope 
(Figure 1.10) because cell division takes place in 
more than one plane. Staphylococci are facultative 
anaerobes capable of generating energy by 
aerobic respiration and by fermentation which 
yields mainly lactic acid. Another feature of the 
genus is the cell wall peptidoglycan structure 
that contains pentaglycine residues in the cross-
bridge in the cell wall peptidoglycan, which 
causes susceptibility to lysostaphin (Plata et al., 2009). S. aureus produces coagulase, which 
interacts with prothrombin in the blood causing plasma to coagulate by converting 
fibrinogen to fibrin. Plasma coagulation is used to distinguish S. aureus from other 
members of the genus which are collectively called coagulase-negative staphylococci. On 
a rich medium, S. aureus forms medium-size “golden colonies”. The golden pigmentation 
of the S. aureus colonies (also the etymological root of the name; ‘aureus’ meaning 
‘golden’ in Latin) is caused by the presence of carotenoids and is reported to be a 
virulence factor protecting the pathogen against oxidants produced by the immune 
system (Plata et al., 2009). 
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1.6.2 Infections  
S. aureus is both a commensal and a pathogen. It can colonize the skin and moist 
squamous epithelium of anterior nares of individuals. At least 20 % of the population is 
permanently colonized by S. aureus, 60 % are intermittent carriers and 20 % never carry 
the organism (Foster, 2004). Colonization significantly increases the risk of infection 
since it provides a reservoir of the pathogen from which the bacteria can be introduced 
when the host immune system is compromised (Kluytmans et al., 1997). S. aureus is 
responsible for a plethora of medical problems (Casey et al., 2007; Plata et al., 2009). The 
most common infections are those of skin and soft tissues, including cellulitis, impetigo 
and soft tissue abscesses, the latter being common in diabetic patients. S. aureus is one of 
the main causes of serious hospital- and community-acquired infections. It is a common 
cause of surgical site infections (SSIs), bone and joint infections such as acute and 
vertebral osteomyelitis often acquired as a result of contamination during surgery. It is 
also a cause of difficult-to-treat infections of catheters and other devices due to its 
propensity to form biofilms (Fitzpatrick et al., 2005). S. aureus is also the most common 
cause of hospital-acquired bacteraemia. A leading cause of haemodialytic bacteraemia, S. 
aureus causes significant morbidity and mortality among renal patients. It is also a major 
cause of endocarditis, another serious deep-seated infection. Ventilator-associated S. 
aureus pneumonia, although uncommon, is associated with high mortality rates. In 
addition it is also responsible for toxin-mediated diseases such as toxic shock syndrome, 
scalded skin syndrome and staphylococcal food-borne diseases. In short, S. aureus is 
capable of causing a wide range of serious infections with morbidity and mortality rates 
of up to 64 % depending on the site of infection and the susceptibility of the particular 
strain (Casey et al., 2007). The pathogenesis of S. aureus reflects on its ability to evade the 
immune system (Foster, 2005), to produce a wide array of virulence factors/toxins, to 
attach firmly to prosthetic material by production of a glycocalyx and an extraordinary 
capability of developing antimicrobial resistance. 
1.6.3 Drug resistance  
S. aureus is a problematic pathogen due to its remarkable ability to develop resistance to 
antibiotics. Believed to be naturally susceptible to the majority of antibiotics that has ever 
been developed, S. aureus has been highly successful in acquiring resistance through 
horizontal transfer of genes from outside sources, chromosomal mutations and antibiotic 
selection (Chambers & Deleo, 2009) (Figure 1.11). Back in 1928, Sir Alexander Fleming’s 
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chance observation of the susceptibility of S. aureus to a substance from a contaminating 
mould led to the discovery of penicillin and marked the beginning of the ‘antibiotic era’. 
The optimism of treatment with this miracle drug was dampened only a few years after 
its use in clinical practice, when penicillin-resistant strains began to emerge. These strains 
produced a plasmid-encoded penicillinase, which hydrolyses the β-lactam ring of 
penicillin that is essential for its antimicrobial activity. Emergence of antibiotic resistance 
in S. aureus since then has been depicted as a series of waves (Chambers & Deleo, 2009) 
(Fig. 1.11). Wave 1, which started after the introduction of penicillin into clinical practice 
in the 1940s, continues 
today. The first pandemic 
antibiotic (penicillin)-
resistant strain is from the 
lineage known as phage 
type 80/81, which 
disappeared after the 
introduction of methicillin, 
an antibiotic from the 
same class but resistant to 
penicillinase. A second 
wave of resistance (wave 2) 
followed shortly after the 
introduction of methicillin. 
Methicillin-resistant 
Staphylococcus aureus (MRSA) 
containing a large mobile 
genetic element called staphylococcal cassette chromosome, mec I (SCCmec), indicated as 
MRSA-I in Fig. 1.11, was isolated. It carries a mecA gene that codes for an alternative 
penicillin-binding protein, PBP2a, with low affinity to the entire β-lactam class of 
antibiotics including penicillins, cephalosporins and carbapenems in contrast to the 
narrow spectrum activity of penicillinase-mediated resistance. Wave 2 lasted until the 
1970s in the form of the Iberian clone. Wave 3 began in the mid to late 1970s with the 
emergence of new MRSA strains, containing new SCCmec allotypes, SCCmecII and 
SCCmecIII (MRSA-II and MRSA-III) marking the ongoing worldwide pandemic MRSA 
in hospitals and healthcare facilities. The increasing burden of MRSA infections in 
 
UFigure 1.11U: The four waves of antibiotic resistance in S. 
aureus (see text) [reprinted by permission from Macmillan 
Publishers Ltd: Nature Reviews Microbiology (Chambers & 
Deleo, 2009), copyright (2009)]. 
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hospitals led to an increase in the use of vancomycin (a glycopeptide antibiotic), the drug 
of “last-resort” against MRSA. The increased selective pressure resulted in the emergence 
of vancomycin-intermediate S. aureus (VISA) strains that are not inhibited in vitro at 
vancomycin concentrations below 4-8 µg/ml. Wave 4 began in the mid to late 1990s and 
marks the emergence of MRSA strains in communities. Community-associated MRSA 
(CA-MRSA) strains, unrelated to hospital strains were susceptible to most antibiotics 
other than β-lactams and contained a new, smaller, more mobile SCCmec allotype, 
SCCmecIV (MRSA-IV) and various virulence factors. A small number of vancomycin-
resistant S. aureus (VRSA) strains have been isolated (first in 2002) exclusively in 
healthcare settings. A recent study estimated that more people die from MRSA bacteria 
than from HIV in the United States (Payne, 2008) emphasizing the need for new drugs 
against this pathogen. 
1.6.4 Novel approaches for finding new drugs 
Historically, most antibiotics have come from a small subset of molecular scaffolds 
whose functional lifetimes have been extended by generations of synthetic tailoring 
(Fischbach & Walsh, 2009). The need for identifying new structural classes/scaffolds of 
compounds has led to two main approaches for finding antibacterials which are target-
based or whole-cell-based testing of compounds in large scale. In S. aureus, whole 
genome sequence information is available for nine strains (Sibbald et al., 2006) including 
those from two clinical strains, isolated from distinct clinical settings representing 
hospital- and community-acquired MRSA (Holden et al., 2004). The genome sequence 
information continues to facilitate the identification of genes involved in virulence, drug-
resistance and for survival. Several potential targets have been proposed in S. aureus 
(Garcia-Lara et al., 2005; Ohlsen & Lorenz, 2007). Many novel targets have been 
identified and validated in S. aureus using molecular genetic tools (Xia et al., 1999; Zhang 
et al., 2000; Ji et al., 2001; Forsyth et al. ,2002; Yin and Ji, 2002; Chaudhuri et al., 2009). 
The future seems to hold some promise, as the growing challenge has led to the 
identification of a few interesting antibacterial drug candidates with novel mechanisms of 
action and a few emerging targets as well (Devasahayam et al., 2010; Fischbach & Walsh, 
2009). 
1.7 Aim of this work 
In S. aureus two genes designated spsA and spsB were identified encoding homologues of 
SPaseI of which only the latter was shown to be essential (Cregg et al., 1996).  SpsB 
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(signal peptidase from Staphylococcus) has also been functionally expressed in E. coli and is 
able to process E. coli preproteins in vivo (Cregg et al., 1996).  It was predicted that SpsA is 
an inactive SPase homologue as it lacks the conserved catalytic residues. The crystal 
structure of SpsB is not available. Nevertheless, a few substrates (for in vitro activity 
assays) and inhibitors have been described in literature. Despite its potential 
attractiveness as an antibiotic target no biochemical data were previously available on 
SpsB. The aim of this work was to characterize the enzyme SpsB in view of its potential 
use as a drug target, to develop and validate in vitro systems for screening of inhibitors 
and finally screen compounds in order to find SPase inhibitors. To realize this, the 
following steps were undertaken: 
 Isolation, purification and functional analysis of S. aureus SpsB (Chapter 2) 
 Biochemical characterization of SpsB (Chapter 3) 
 Development and validation of in vitro inhibition assays for SpsB (Chapter 4) 
 High-throughput screening of compounds against SpsB and analysis of potential 
hits (Chapter 5)
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Chapter 2: Isolation, purification and functional analysis of S. 
aureus SpsB  
In this chapter, we describe the purification of full-length and truncated SpsB derivatives 
of S. aureus and their functional characterization. In order to find out the effect of 
removal of the hydrophobic transmembrane segment at the N-terminus of the enzyme 
(the catalytic domain being located at the C-terminus), a truncated derivative of SpsB was 
designed and purified. Another truncated derivative, identical in sequence to the one 
mentioned above except for a point-mutation replacing the catalytic Ser with Ala, was 
purified. This truncated active-site mutant was designed for another study (crystallization 
trials) and was used in this work as a negative control in the activity assay described in 
chapter 3. A predicted native substrate of SpsB, Immunodominant staphylococcal 
antigen A precursor (pre-IsaA) was also isolated and purified for demonstration of in vitro 
activity of the purified SpsB. 
2.1 Results 
2.1.1 Cloning and purification of the full-length SpsB and the IsaA 
precursor 
The gene encoding SpsB was amplified by PCR using primers which were designed to 
incorporate the following modifications: the incorporation of an NdeI and an EcoRI 
restriction site at the 5’ and 3’ end, respectively and a hexa-histidine-encoding sequence 
for obtaining a His-tag at the N-terminus of the produced protein to facilitate 
purification.  The fragment of expected size and correct sequence of spsB was cloned 
after the T7 promoter in the pET-3a plasmid. The full-length SpsB (predicted MW=22.5 
kDa, including the hexa-his tag) was purified from E. coli BL21(DE3)pLysS harbouring 
the plasmid pET-fl-SpsB and analyzed by SDS-PAGE.  The purification of the full-
length SpsB normally yielded samples of sufficient purity (>95 %) and concentration 
(~30-40 µM) for functional characterization (Figure 2.1a). The gene encoding pre-IsaA 
was amplified by PCR using oligos that were also designed to incorporate NcoI and EcoRI 
restriction sites and sequences encoding a hexa-histidine tag and a c-Myc tag at the N- 
and C-terminal end of the expressed protein, respectively.  The c-Myc tag was included 
to facilitate immunodetection of the protein.  The gene, after confirming the correct 
sequence, was cloned in pET-23d and expressed in E. coli BL21(DE3)pLysS.  Pre-IsaA 
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(predicted MW=26.2 kDa, including hexa-his and c-Myc tag) was purified, refolded and 
used in the in vitro assay after analysis by SDS-PAGE (Figure 2.1b).  
 
 
2.1.2 Design, cloning and purification of N-terminally truncated SpsB  
Topology prediction for SpsB (sequence source: http://cmr.jcvi.org/tigr-
scripts/CMR/CmrHomePage.cgi) by TMHMM (Krogh et al., 2001) and Porter server 
(Pollastri & McLysaght, 2005) indicated the presence of 
a single N-terminal transmembrane segment important 
for membrane anchoring (Fig. 2.2).  A truncated 
derivative, which we designated as tr-SpsB, was 
designed to obtain a soluble derivative of SpsB devoid 
of the transmembrane segment (box A) but retaining 
the amino acids in the conserved box B region, located 
in its vicinity (Fig. 3.9, chapter 3). Similarly, a second 
truncated derivative designated as tr-mut-SpsB with an 
identical sequence except for the catalytic Ser being 
replaced by an Ala was obtained by a double-PCR 
approach (designed by Geukens N, unpublished data). 
N-terminally hexa-his-tagged tr-SpsB and tr-mut-SpsB (predicted MW=18.2 kDa) were 
 
UFigure 2.1: Purified SpsB and IsaA on gel U. The N-terminally hexa-his-tagged proteins were 
overproduced in E. coli, purified by Ni2+ affinity chromatography and analyzed by SDS-PAGE 
followed by CBB staining.  (a) SpsB purified under native conditions.  Lane 1, molecular weight 
marker; Lane 2, flow through; Lanes 3 & 4, column wash with buffer containing 10 and 20 mM 
imidazole respectively; Lanes 5 to 7, elution fractions in buffer containing 100 mM imidazole; 
Lanes 8 to 10, elution fractions in buffer containing 250 mM imidazole. (b) Pre-IsaA purified 
under denaturing conditions. Lane 1, molecular weight marker; Lanes 2 and 3, sample in elution 
buffer (pH 4.5). 
 
 
UFigure 2.2 U: A schematic 
representation of membrane 
topology of SpsB showing the 
conserved boxes. 
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found to be in the soluble fraction upon production in E. coli BL21 (DE3)pLysS 
harbouring the respective plasmids and could be purified under native conditions from 
the cytoplasmic fraction by Ni2+ affinity chromatography.  The yield of the truncated 
active form was low compared to the truncated mutant and also required an additional 
step of cation exchange chromatography prior to its use in the in vitro assays while the 
yield of the truncated mutant was much higher (Figure 2.3).  The huge difference in the 
yield between tr-SpsB and tr-mut-SpsB is surprising as the two proteins are identical 
except for a Ser residue replaced by an Ala in the latter. 
 
2.1.3 In vitro preprotein processing by SpsB  
The choice of the preprotein substrate was made after a preliminary analysis of secreted 
proteins indicated in the genomic sequence data of S. aureus.  The criteria for selection of 
the substrate were a good prediction on the presence and the location of the signal 
peptide cleavage site as indicated by SignalP 3.0 server (Bendtsen et al., 2004) and a non-
indication as a general protease.  The latter is not desirable because it could degrade the 
signal peptidase itself.  Pre-IsaA was selected as the substrate for this assay.  IsaA was 
first identified as one of the four proteins expressed in vivo during sepsis caused by 
methicillin-resistant S. aureus (Lorenz et al., 2000).  It is a lytic transglycosylase and has 
been reported to be important for the virulence of S. aureus along with another paralogue 
SceD (Stapleton et al., 2007), which is also a substrate of the signal peptidase SpsB.   
 
 
UFigure 2.3: Purified truncated SpsB derivatives on gel. U tr-SpsB was purified from the 
cytoplasmic fraction of E. coli harbouring pET-tr-SpsB, by nickel affinity chromatography 
followed by cation exchange. Purified protein was separated on SDS/PAA gel followed by 
CBB staining. (a) Lane 1, molecular weight marker; lane 2, purified tr-SpsB (b) tr-mut-SpsB 
was purified from E. coli harbouring pET-tr-SpsB, by nickel affinity chromatography and 
the purified fractions were analysed as described above. Lane 1, molecular weight marker; 
Lane 2, flow through; Lanes 3 & 4, column wash with buffer containing 10 and 20 mM 
imidazole respectively; Lanes 5 to 7, elution fractions in buffer containing 100 mM 
imidazole; Lanes 8 to 10, elution fractions in buffer containing 250 mM imidazole. 
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U Figure 2.4: Preprotein processing by SpsB (full-length) (a) as function of time (b) in 
comparison with the tr-SpsB.U (a) pre-IsaA (10 mM) was incubated with the full-length 
SpsB (2 µM) at 37° C in the assay buffer for different time periods. The proteins were 
separated on 12.5 % (w/v) SDS-PAA gels and analyzed by Western blotting and 
chemiluminescent detection (a) Lane 1, SpsB (control); Lane 2, pre-IsaA (control); Lane 3, 
SpsB and pre-IsaA at time=0; Lanes 4 to 10, pre-IsaA processing by SpsB with increase in 
time ; Lane 11, 900 min incubation followed by addition of fresh SpsB (2 µM final) and a 
further incubation for 3 h. (b) The assay was set up as described above except that the final 
concentration of SpsB was 1 µM and incubation time was fixed to 15 h. Lane 1, pre-IsaA 
(control); Lane 2, SpsB full-length (control); Lane 3, SpsB truncated (control); Lane 4, pre-
IsaA processed by SpsB full-length; Lane 5, pre-IsaA processed by truncated SpsB. 
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The in vitro assay was carried out in the presence of a protease inhibitor cocktail and the 
reactions were stopped at different time intervals ranging from 0 to 15 h.  Analysis of the 
assay products by means of immunodetection of pre-IsaA/IsaA, revealed the presence of 
two bands (Figure 2.4) in the sample containing the preprotein substrate and SpsB.  The 
upper band corresponds to the unprocessed preprotein and the lower one to the mature 
protein (predicted MW=22.5 kDa). As seen in Figure 2.4, the substrate remained 
unprocessed in the absence of the enzyme.  The amount of preprotein processed 
increased over time (Figure 2.4a).  After 15 hours (900 min), unprocessed protein 
remained and the addition of fresh SpsB followed by incubation for 3 hours did not 
result in any significant improvement in processing.  Similar observations of incomplete 
processing have been made previously with in vitro assays involving the signal peptidases 
and preproteins (Geukens et al., 2004; Peng et al., 2001a; Talarico et al., 1993; van 
Roosmalen et al., 2001) and it has been suggested that the remaining preprotein is 
probably in an unprocessable state. The specificity of the preprotein cleavage by SpsB 
was confirmed by N-terminal sequence analysis of the mature protein obtained.  The 
substrate was cleaved at the predicted site (Figure 3.2, chapter 3), following the (-1,-3) or 
“Ala-X-Ala” rule (Nielsen et al., 1997).  Additionally, the substrate was also processed by 
the truncated SpsB (tr-SpsB) lacking the transmembrane segment residues but containing 
the active-site Ser. A comparison of preprotein processing by the two enzymes is shown 
(Fig 2.4b).  
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2.2 Discussion  
In this chapter, we describe the purification of SpsB and a native preprotein substrate, 
pre-IsaA, and demonstrate the in vitro processing of the substrate by the SPase as the first 
step in its functional characterization. SpsB has been purified earlier for use in in vitro 
assays involving synthetic peptide substrates (for references, see table 1.1). We also 
demonstrated the activity of a truncated derivative of SpsB lacking the hydrophobic 
residues in the predicted transmembrane region. This indicates that the residues in the 
transmembrane segment are not essential for the cleavage fidelity of SpsB as it also 
cleaves the preprotein. Retention of activity and cleavage fidelity has also been observed 
in truncated versions of E. coli LepB and B. subtilis SipS (Carlos et al., 2000b). Truncated 
derivatives of SpsB are interesting candidates for crystal structure determination as this 
process can be tedious and time-consuming in case of membrane proteins. Although 
several membrane proteins have been crystallized, no crystal structure is currently 
available for the full-length SpsB or for any other bacterial SPaseI. The problem of in vitro 
self-cleavage is another factor contributing to the challenge of structure determination of 
SPaseI by X-ray crystallography. In this respect, the truncated active-site mutant of SpsB 
would be an interesting candidate for crystallization as in theory this mutant protein 
would be more stable than the native full-length SpsB. Pity enough, no crystals could be 
obtained with this truncated mutant of SpsB (Prof. R. Loris, VUB, personal 
communication). However, crystallization is beyond the focus of this doctoral work and 
the truncated active site mutant was intended to serve as a control in the in vitro assay (see 
chapter 3).   
 
Secretomic analysis of sequenced S. aureus strains revealed that 58 proteins from a total 
~2,600 encoded in the genome contain a potential SpsB recognition and cleavage site, of 
which 33 have been identified (Sibbald et al., 2006). These proteins seem to be largely 
comprised of enzymes such as proteases and other factors such as fibrinogen- and IgG- 
binding proteins that are required for residing in the human host. Among the predicted 
substrates of SpsB are many known extracellular staphylococcal virulence factors such as 
exotoxins, enterotoxins (SEM, SEN and SEO), haemolysins, TSST-1, leukotoxins (LukD 
and LukE) and a secretory antigen SsaA homologue (Sibbald et al., 2006). Furthermore, it 
has been shown that SpsB plays a role in the agr quorum-sensing system which is 
important for biofilm formation and virulence (Kavanaugh et al., 2007). It is also 
interesting to note that biofilm-associated proteins (Baps), a family of surface proteins 
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involved in biofilm formation, are substrates of SpsB (Lasa & Penades, 2006). In essence, 
SpsB is an essential enzyme in S. aureus and also plays a major role in processing proteins 
necessary for biofilm growth, virulence, damaging the host tissues (toxins), conferring 
antibiotic resistance (β-lactamase) and quorum sensing, enhancing the significance of 
discovering SPase inhibitors.  
 
The genome of S. aureus also contains a second gene (spsA) encoding a homologue of 
SPasesI immediately upstream of the spsB gene. The two genes are separated by a short 
spacing of 15 bases between the 3’ end of spsA and the 5’ end of spsB implying either 
cotranscription of the two genes or the presence of a cryptic promoter for spsB 
transcription within the 3’-terminal coding region of spsA (Cregg et al., 1996). SpsA and 
SpsB are proteins of 174 and 191 residues with predicted molecular weights of 
approximately 20.1 and 21.6 kDa respectively. SpsA has a sequence that is similar to 
known SPases but as seen in Table 2.1, it lacks the catalytic Ser or Lys required for 
SPaseI activity. It has also been shown that SpsB, but not SpsA, is responsible for the 
removal of the N-terminal leader of AgrD, the precursor of AIP (auto-inducing peptide) 
which controls the agr-quorum sensing system (Kavanaugh et al., 2007). Thus, as of now, 
the role of SpsA (if any) in protein secretion is not known. Apparently inactive SPase 
homologues missing one of the catalytic residues (Ser or Lys) are also present in S. 
epidermidis (Sip1), S. carnosus (SipA), Streptococcus mutans, Streptococcus pyrogenes, and Borrelia 
burgdorferi. However, there are no data available on the role of these proteins either.  
2.3 Experimental procedures 
2.3.1 Bacterial strains, growth conditions and plasmids 
E. coli strains TG1 (Sambrook et al., 1989) and BL21(DE3)pLysS (Studier & Moffatt, 
1986) used for genetic manipulations and protein expression, respectively, were grown at 
UTable 2.U1: Comparison of the residues in the conserved boxes in E. coli LepB, S. 
aureus SpsB and SpsA. 
SPase Box B Box D Box E 
Consensus   SMxPTL  YxKRxxGxPGD GDNxxxSxDSR  
LepB SGSMMPTL YIKRAVGLPGD GDNRDNSADSR  
SpsB GESMDPTL  YVKRVIGVPGD GDNREVSKDSR  
SpsA NNDMSPTL  YTSRIIAKPGQ NDHDNNQHDSR  
The identical residues in the boxes are highlighted in blue. The residues present in the place of 
catalytic Ser and Lys in SpsA are underlined. 
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37 °C in Luria-Bertani (LB) medium, supplemented with ampicillin (50 µg ml-1) or 
chloramphenicol (25 µg ml-1), where applicable.  The plasmids used in this study are 
listed in table 2.2.  
2.3.2 General molecular genetic techniques 
DNA manipulations in E. coli were carried out as described in Sambrook et al., 1989. 
Plasmid DNA isolation and PCR clean-up were carried out using commercial kits 
(Promega) according to the manufacturer’s instructions.  
2.3.3 Cloning of spsB (wild-type and derivatives) and isaA 
The gene encoding SpsB was amplified by PCR from S. aureus ATCC 65388 genomic 
DNA as template using the oligos fl-SpsB5 and fl-SpsB3 for the full-length and oligos tr-
SpsB5 and fl-SpsB3 for the truncated derivative, respectively.  The oligonucleotides were 
designed based on the spsB gene sequence (http://cmr.jcvi.org/tigr-
scripts/CMR/CmrHomePage.cgi).  The oligonucleotide sequences are given in table 2.3 
and as indicated, a hexa-histidine-encoding sequence was included at the 5’ end.  The 
resulting PCR-amplified DNA fragments were first cloned in pGEM-T Easy (Promega) 
and subsequently cloned as NdeI/EcoRI  fragments into the pET-3a (Novagen) 
expression plasmid which was also cut with the same restriction enzymes.  
 
The gene isaA was amplified from S. aureus genomic DNA using oligos pIsaA5 and 
IsaA3Myc, the sequence of which is given in table 2.3.  The forward primer pIsaA5 
contained a hexa-histidine-encoding sequence and the reverse primer IsaA3Myc 
contained a c-Myc-encoding sequence.  PCR-amplified DNA was cloned in pGEM-T 
Easy and subsequently cloned as a NcoI/EcoRI fragment into the corresponding sites of 
pET-23d (Novagen).  
2.3.4 Expression and purification of full-length SpsB 
Expression of the protein was carried out essentially as previously described (Studier & 
Moffatt, 1986).  E. coli BL21(DE3)pLysS cells harbouring pET-fl-SpsB were grown in 
600 ml LB medium at 37 °C until the optical density at 600 nm (OD600) reached 0.6.  
Isopropyl-β-D-thiogalactopyranoside (IPTG) was then added to a final concentration of 
1 mM.  Three hours later, the cells were pelleted by centrifugation (10 min, 4,000 x g, 4 
°C).  
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For purification of full-length SpsB, the cells were resuspended in 20 ml of 50 mM Tris-
HCl pH 8, containing 20 % sucrose and lysed by three passages through a French 
pressure cell at 15,000 psi.  After removal of the cell debris by centrifugation (10 min, 
12,000 x g, 4 °C), the cell lysate was subjected to ultracentrifugation at 100,000 x g for 2 
h.  The pellet was resuspended in 5 ml of buffer A (50 mM NaH2PO4, 300 mM NaCl, 
pH 8.0) containing 10 mM imidazole and 0.5 % Triton X-100.  The sample was 
transferred onto a column loaded with Nickel-Nitrilo-tri-acetic acid (Ni2+-NTA) 
sepharose and pre-equilibrated with buffer A containing 10 mM imidazole.  The column 
was placed on ice on a rotary shaker (45 rpm) for 1h. The column was washed twice with 
buffer A containing 10 and 20 mM imidazole, respectively, in the presence of 0.05 % 
Triton X-100.  Samples were eluted in two steps, first with buffer A containing 100 mM 
imidazole and then with buffer A containing 250 mM imidazole in the presence of 0.05 
% Triton X-100.  For analysis of purity, 4 µl of 6 x SDS-PAGE loading buffer was added 
to 20 µl of different elution fractions and incubated at 37 °C for 10 min followed by 
loading on 12.5 % SDS-PAA gels.  After separation of the proteins (30 mA/minigel), the 
gel was stained with Coomassie Brilliant Blue (CBB).  
2.3.5 Expression and purification of the truncated SpsB 
For production of the truncated SpsB derivatives, E. coli BL21(DE3)pLysS was 
transformed with the plasmids pET-tr-mut-SpsB (Geukens N, unpublished) or pET-tr-
SpsB. The cell pellets obtained after centrifugation (10 min, 4,000 x g, 4 °C) from 600 ml 
culture of E. coli BL21(DE3)pLysS harbouring the respective plasmids were resuspended 
in 10 ml of buffer A with 10 mM imidazole and passed through a French pressure cell at 
15,000 psi, thrice.  After centrifugation (10 min; 12,000 x g), the clarified sample was 
subjected to Ni2+-affinity chromatography as described for the full-length SpsB.  In case 
of tr-SpsB, the eluted fractions were pooled and subjected to buffer exchange on a PD-
10 desalting column (GE Healthcare).  The sample eluted in 50 mM HEPES buffer, pH 
7.4 was further purified by cation exchange chromatography using a HiTrap SP FF 
column on the AKTAprimeTM plus HPLC system (GE Healthcare) as described by the 
manufacturer.  The fractions containing tr-SpsB were passed through a PD-10 desalting 
column and eluted in 50 mM Tris-HCl, pH 8.  The purified protein was observed on 
CBB-stained SDS-PAA gel.  
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2.3.6 Expression and purification of preprotein immunodominant 
staphylococcal antigen A (pre-IsaA) 
Pre-IsaA (with a hexa-his-tag at the N-terminus and a c-Myc-tag at the C-terminus) was 
expressed in E. coli BL21(DE3)pLysS cells harbouring pET-IsaA. IPTG induction was 
carried out as described above.  Additionally, sodium azide (1 mM final concentration) 
was added to prevent the translocation of the preprotein and subsequent cleavage of the 
signal peptide.  Pre-IsaA was purified under denaturing conditions (8 M urea) on a Ni2+-
NTA column as recommended by the manufacturer (The QIAexpressionistTM, Qiagen).  
Removal of urea and subsequent protein renaturation was carried out using PD-10 
columns.  The sample was eluted from the column in buffer containing 50 mM Tris-HCl, 
pH 8 and 0.5 % Triton X-100.  The purified protein was then analyzed by SDS-PAGE 
and Western blotting. 
2.3.7 In vitro activity assay for SpsB using the preprotein pre-IsaA  
The concentrations of the purified proteins were determined by a protein assay (Bio-Rad) 
based on the Bradford method.  The enzyme SpsB (pre-treated with a protease inhibitor 
cocktail tablet (Complete, mini, EDTA-free, Roche Diagnostics) and pre-IsaA were 
added to the assay buffer (50 mM Tris-HCl, pH 8 with 0.5 % Triton X-100) to get final 
concentrations of 2 and 10 µM, respectively. Reaction mixtures (total volume of 20 µl) 
were incubated at 37 °C for different periods of time ranging from 0 to 15 h. The 
reactions were stopped by addition of 4 µl of 6 x SDS-PAGE sample loading buffer.  
The proteins were separated by SDS-PAGE using 12.5 % (w/v) PAA-resolving gels and 
subsequently transferred to a nitrocellulose membrane (Macherey Nagel).  For 
immunodetection, anti-cMyc (DiaMed) and anti-mouse IgG (whole-molecule)-alkaline 
phosphatase antibodies produced in rabbit (Sigma) were used. Chemiluminescent 
detection was carried out using ‘Western StarTM’ kit (Tropix) as described by the 
manufacturer.       
2.3.8 N-terminal sequencing 
The proteins were separated by SDS-PAGE using 12.5 % SDS-PAA gels followed by 
electroblotting onto a polyvinylidene difluoride (PVDF) membrane.  The bands were 
visualized by staining with Coomassie blue R-250 and destaining with 100 % methanol.  
The protein of interest (IsaA, in this case) was excised from the membrane and the N-
terminal amino acid sequence was determined by automated Edman degradation. 
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Table 2.2: Plasmids used in the work 
 
 
Table 2.3: Oligonucleotides used in this work 
Restriction sites are underlined, hexa-histidine-encoding sequence is italicized and c-myc-
encoding sequence is indicated in bold. 
Plasmid Description Source 
pGEM-T Easy 
 
3’-T overhang suited for cloning PCR products; lacZ; Ampicillin 
resistance (bla) 
Promega 
pET-3a T7 promoter ; MCS; Ampicillin resistance (bla) Novagen 
pET-23d T7 promoter ;  MCS ; Ampicillin resistance (bla) Novagen 
pET-fl-SpsB pET-3a derivative containing hexa-his-encoding sequence (5’-
end) and spsB between NdeI and EcoRI 
This work 
pET-tr-SpsB pET-3a derivative containing hexa-his-encoding sequence and 
5’-end truncated spsB between NdeI and EcoRI 
This work 
 pET-tr-mut-
SpsB 
Identical to pET-tr-SpsB except for a single nucleotide 
difference to encode an active-site mutant (catalytic Ser →Ala) 
of tr-SpsB 
Geukens N, 
(unpublished) 
pET-pIsaA pET-23d derivative containing hexa-his- (5’-end) and c-myc- (3’-
end) encoding sequence with pre-IsaA (Immunodominant 
staphylococcal antigen A precursor) gene between NcoI and 
EcoRI.  
This work 
 
Oligonucleotide Sequence 
Restriction 
site 
fl-SpsB5 5’-TAUCATATG UCACCATCACCATCACCATAAAAAAGAATTATTGGAATGGATTATTTC-3’ NdeI 
fl-SpsB3 5’-TAUGAATTCUTTAATTTTTAGTATTTTCAGG-3’ EcoRI 
tr-SpsB5 5’-TAUCATATG UCACCATCACCATCACCATATTGTTACACCATATA-3’ NdeI 
pIsaA5 5’TAUCCATGG UCACATCACCATCACCATCACAAAAAGACAATTATGGC3’ NcoI 
IsaA3Myc 5’TAUGAATTCUTTACAGATCCTCCTCTGAGATGAGCTTCTGCTCGAATCCCCAAGCACCTAAACC3’ 
 
EcoRI 
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UFigure 3.1: Emission scan of the reaction products 
containing SceD peptide with or without SpsB.U  The 
test reactions contained SpsB (1 µM) and the synthetic 
peptide SceD (10 µM), while the control reaction 
contained only the peptide substrate.  The samples were 
incubated at 37 °C for 15 h followed by measurement of 
the fluorescence intensity as a function of wavelength 
(ex= 340; em = 510). 
Chapter 3: Biochemical characterization of SpsB 
In this chapter, the in vitro behaviour of the purified full-length SpsB with respect to its 
stability, pH requirement and enzymatic activity, is described. In order to obtain 
quantitative data on the SpsB activity and given that the preprotein assay is semi-
quantitative at best, synthetic peptide substrates were tested and one of them was used to 
optimize another in vitro assay for SpsB. This assay was used to compare the activities of 
the full-length SpsB with its truncated derivatives.  
3.1 Results 
3.1.1 A continuous fluorometric assay for SpsB and measurement of its 
specific enzymatic activity  
A FRET-based assay was designed for SpsB. The substrate used was an internally 
quenched peptide based on the signal peptide sequence of S. epidermidis SceD protein, 
coupled to a DABCYL/EDANS FRET-pair.  SpsB was found to cleave this peptide 
efficiently in the presence of 
protease inhibitor cocktail, to 
which the bacterial type I 
SPases are resistant (Fig. 3.1). 
The hydrolysis of the peptide 
was measured by the increase 
in fluorescence on a 
microplate reader using 
excitation and emission 
wavelengths of 340 and 510 
nm respectively. No increase 
in fluorescence was observed 
in the presence of the 
peptide or the enzyme only. 
The validation of this assay is 
described in chapter 4. The 
specificity of the proteolytic 
reaction of the SceD peptide 
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UFigure 3.2: Signal peptidase recognition sequence and cleavage sites of the SpsB 
substrates used in this study. U Part of the sequence of the IsaA precursor (upper row) and 
the sequence of the SceD peptide (lower row) with signal peptidase cleavage sites indicated. 
The signal peptidase recognition sequence which consists of small aliphatic residues at 
positions -1 and -3 relative to the cleavage sites, is indicated in bold.
 
UFigure 3.3: A comparison of the activities of the full-length and the truncated SpsB 
derivatives. U (a) The enzyme assay was performed using 5 µM final concentration of the 
synthetic SceD peptide (where [S]<<Km) in the presence of full-length SpsB (2 µM), truncated 
SpsB (2 µM) or an active-site mutant (10 µM) in a reaction buffer at 37 °C.  Fluorescent 
intensity was measured as a function of time using a Tecan InfiniteTM M200 microplate reader.  
(b) The specific enzymatic activity kcat/Km of full-length and truncated SpsB were compared 
using varying enzyme concentrations and a fixed concentration of the peptide substrate (5 µM 
for full-length and 2.5 µM for truncated SpsB).  The pseudo-first order rate constant Kobs was 
plotted as a function of enzyme concentration.   
 
by SpsB was analysed by HPLC followed by electrospray ionization mass spectrometry 
(ESI-MS), (by Bockstael K as described in Bockstael et al., 2009a). Cleavage of the 
fluorogenic synthetic SceD peptide by SpsB occurred specifically at the predicted site 
located at the A-S bond. The sequence and cleavage site of the SceD peptide in 
comparison with the SpsB cleavage site of the preprotein IsaA are indicated in Fig. 3.2. 
 
It was observed that at high substrate concentrations (20 µM), the linear correlation 
between the fluorescence and the substrate concentration is lost due to inner filter effect.  
Inner filter effect is the phenomenon observed when the fluorescent light is absorbed by 
quenching groups on neighbouring substrates or cleaved product molecules, allowing 
only a fraction of light to be detected by the instrument.  Therefore, only kcat/Km could be 
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measured using the condition [S] Km.  Consistent with this condition, the time-course 
FRET assay with the enzyme followed simple first order kinetics.  The pseudo-first order 
rate constant (kobs) derived from these curves was directly proportional to the enzyme 
concentration throughout the experimentally accessible range of concentrations (0.1 to 
10 µM). The apparent second order rate constant kcat/Km or specific enzymatic activity of 
the full-length SpsB was found to be 1.85 ± 0.13.103 M-1s-1 (Fig. 3.3a,b).   
 
The specific activity of the truncated derivative (tr-SpsB) was determined under the same 
conditions except that in order to achieve complete processing, the final substrate 
concentration used for the truncated enzyme was 2.5 µM.  The apparent second order 
rate constant kcat/Km of the truncated enzyme was found to be 59.4 ± 6.4 M-1s-1 (Fig. 
3.3a,b) in the presence of 0.5 % Triton X-100 (Fig. 3.3a). This 30-fold reduction in the 
specific activity of the truncated SpsB (tr-SpsB), compared to the full-length enzyme, 
confirms the importance of the transmembrane segment for optimum activity of the 
signal peptidases.  Additionally, the truncated mutant (tr-mut-SpsB) in which the catalytic 
Ser is replaced by Ala was used as a control in the FRET assay.  This mutant had a 
kcat/Km value of 4 ± 0.8 M-1 s-1 which is 14.8-fold lower than the active truncated (tr-SpsB) 
and 462-fold lower than the full-length enzyme (Fig. 3.3a).  This also confirms that the in 
vitro activity is specifically due to the enzyme SpsB and not due to background activity of 
LepB of E. coli (which was used as the host for overproduction of SpsB). 
 
 
UFigure 3.4: Effect of detergent (Triton X-100) on the activity of tr-SpsB. U Specific 
enzymatic activity of tr-SpsB was determined in a FRET assay with SceD and tr-SpsB (at 2.5 
µM and 5 µM final concentrations respectively) in the presence (at different concentrations) and 
absence of Triton X-100. The specific enzymatic activity of tr-SpsB at the highest detergent 
concentration (1 %) was fixed to 100 % and the remaining samples are represented against this 
value. 
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UFigure 3.5: Effect of pH on the SpsB activity. U SpsB (1 µM) was added to different buffers 
varying in pH from 5 to 12 and incubated for 5 min at 37 °C. The fluorogenic synthetic peptide 
SceD was added at a final concentration of 5 µM to start the reaction.  Fluorescence intensity was 
measured as a function of time.  The figure is a representative of three independent experiments. 
It was also observed that the non-ionic detergent Triton X-100 increases the activity of 
tr-SpsB, while the addition of sodium deoxycholate (ionic) or sulfobetain SB12 
(zwitterionic) detergents render the enzyme inactive (data not shown). The effect on the 
activity of tr-SpsB in the presence or absence of Triton X-100 was studied in the FRET 
assay. Maximum activity of tr-SpsB was observed at 1 % Triton X-100, although the 
difference between 0.5 % and 1 % detergent is comparatively minor and the specific 
activity was halved in the absence of the detergent (Fig. 3.4). 
 
3.1.2 Activity at varying pH and the pH-rate profile of SpsB 
The pH-dependence of the SpsB activity was initially studied by monitoring the in vitro 
preprotein processing by SpsB in reaction buffers varying in pH from 2 to 12.  The 
enzyme was found to be active at a wide pH range (pH 5 to 12) but not at or below pH 
4, in three independent experiments (data not shown).  An assessment of the amount of 
preprotein processed at varying pH did not yield sufficient quantitative data, and 
therefore the FRET-assay was used to study the effect of pH on enzyme activity.  The 
stability of the synthetic SceD substrate was determined by incubating the peptide in 
different buffers in the absence of the enzyme.  No increase in fluorescence was 
observed over the entire range of pH from 2 to 12 during the time-course assay (data not 
shown), confirming its suitability for this purpose.  The enzyme reactions were carried 
out in different buffers from pH 5 to 12 and the increase in fluorescence was observed as 
a function of time (Fig. 3.5). The curve obtained for pH 12 could not be fitted to obtain 
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U 
 
Figure 3.6: pH-rate profile of SpsB U.  The calculated specific enzymatic activities (kcat/Km) 
obtained after carrying out the reactions in buffers with varying pH from 4 to 12 were fitted 
using the equation for a complex bell-shaped curve.  The results shown are an average of three 
independent experiments.   
the exact kcat/Km value (Fig. 3.5).  However, the activity at pH 12 appears to be lower in 
terms of the initial velocity and to plot the pH-rate profile, the approximate kcat/Km value 
obtained was used.  The pH-rate profile obtained by plotting kcat/Km versus pH was fitted 
with the equation (Eqn.1) for a complex bell-shaped curve (Fig. 3.6).  The activity of 
SpsB is maximum activity at pH 7.9 ± 0.2.  The high pH optimum of SpsB in vitro is 
consistent with those reported for the other SPases and is in agreement with the catalytic 
mechanism. 
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The curve obtained from the pH-rate profile (Fig. 3.6) was not a typical single bell-
shaped curve as there appeared to be another smaller peak around pH 11.  The apparent 
pKa values for the free enzyme are approximately 6.6 and 8.7 with possibly another pKa 
around 11.8.  The presence of two peaks in the pH-dependence curve (Fig. 3.6) and the 
high pKa1 suggests that two acid groups can play the role of acid catalyst as represented 
in Scheme 1 (Brocklehurst & Dixon, 1976; Tipton & Dixon, 1979).  Deprotonation of 
ESH2+ with a pKa2 of 8.7 decreases the rate of the catalyzed reaction.  Further 
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Figure 3.7: Stability of SpsB (a) at different temperatures and (b) in the presence of 
arylomycin A2 (a) The stability of SpsB was tested by placing 20 µl aliquots of purified 
SpsB at different temperatures for up to 9 days. The proteins were analyzed by SDS-PAGE 
followed by staining with CBB. L, molecular weight marker; remaining lanes show the full-
length SpsB and an additional band corresponding to the self-cleavage product (sc-SpsB) 
resulting from incubation for 4, 6 and 9 days respectively at 4 °C, 27 °C or 37 °C; SpsB 
stored at -80 °C represents the control reaction (0 h). (b) Purified full-length SpsB was 
incubated without and with arylomycin (200 µM final concentration) at 37 °C for 7 days 
and analyzed by SDS-PAGE. Lane 1, molecular weight marker; Lane 2, SpsB without 
arylomycin (time=0); Lane 3, SpsB without arylomycin incubated for 7 days; Lane 4, SpsB 
with arylomycin (time=0); Lane 5, SpsB with arylomycin incubated for 7 days. 
deprotonation of ESH+ with a pKa3 around 11.8 probably ends the catalytic reaction 
(Scheme 1).  The kcat/Km values were calculated using Eqn 1.   
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3.1.3 Stability and the effect of temperature on the in vitro activity of SpsB 
Since SPases are known to undergo degradation upon incubation or storage over time, 
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SPase, Bacterial species                                                   Alignment   
 
SpsB, S. aureus (This chapter)                                          VTPYTIKG↓ESMDPTLKDGE 
Spi, S. pneumoniae (Peng et al., 2001a)                               WSNVRVEG↓HSMDPTLADGE 
SipS, B.subtilis (van Roosmalen et al., 2000)         FAPYVVDGES↓MEPTLHDRE 
 
UFigure 3.8: Site of self-cleavage of SpsB, in comparison with Spi and SipS U. Alignment of 
SpsB with Spi and SipS sequences showing the sites of self-cleavage. The -1 and -3 positions 
relative to the cleavage sites are in bold, the catalytic serine is in italics and the site of self-cleavage 
is indicated with an arrow. 
 
we tested the stability of SpsB (full-length) by storing or incubating the enzyme at 4 °C, 
27 °C or 37 °C for different lengths of time in the presence of general protease 
inhibitors.  In the sample stored at 4 °C for 9 days, only one band corresponding to the 
native SpsB was observed (Fig. 3.7a).  However, the kcat/Km of this sample was 70 M-1s-1 
which was 18.5-fold lower compared to the enzyme stored at -80 °C for the same time 
period.  After 4 days of incubation at 27 °C, apart from the band corresponding to the 
native SpsB, a smaller protein was found (MW~18 kDa) which we designated as sc-SpsB.  
The amount of sc-SpsB increased over time and with increasing temperature.  The 
addition of the SPase inhibitor arylomycin A2 blocked the appearance of sc-SpsB (Fig. 
3.7b), suggesting that this protein fragment results from intermolecular self-cleavage.  
3.1.4 In vitro self-cleavage 
The N-terminal sequence analysis of the self-cleavage product sc-SpsB revealed that the 
enzyme was cleaved one amino acid before the catalytic serine (Fig. 3.8).  The self-
cleavage site resembles the signal peptide cleavage site following the (-1,-3) rule for SPase 
recognition, as seen in the case of LepB, SipS and Spi.  A comparison of the SpsB and 
Spi self-cleavage sites shows that both proteins are cleaved at the same position, while in 
case of SipS from B. subtilis, the cleavage site is located immediately after the catalytic 
serine (Fig. 3.8).  
 
It has been reported that the self-cleavage products of Spi and SipS have no SPase 
activity.  The self-cleavage site in E. coli LepB is not in the vicinity of the catalytic Ser and 
the self-cleavage product had a 100-fold less specific activity compared to the native 
enzyme (Talarico et al., 1991). We tested the self-cleavage product sc-SpsB and also 
found it to be inactive at the SPase concentration normally used in the FRET assay (1 
µM).   
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UFigure 3.9: N-terminal region of the SpsB sequence showing the difference between the 
truncated SpsB (tr-SpsB) and the self-cleavage product (sc-SpsB) U. The starting points of the 
truncated SpsB and the self-cleavage product of SpsB are indicated in the SpsB sequence. The 
prediction of the transmembrane segment (TMS) was carried out using Porter server (Pollastri & 
McLysaght, 2005). The predicted TMS is in bold and the catalytic serine in italics. The conserved 
box B (Paetzel et al., 2002b) is highlighted.  
 
A very low residual activity of the self-cleavage product was found when the 
concentration of sc-SpsB was greatly increased (data not shown).  Interestingly, the 
inability of sc-SpsB to cleave the substrate contrasts with the in vitro activity of tr-SpsB 
under standard conditions.  Truncated SpsB has nine additional amino acids at the N-
terminus compared to sc-SpsB and three of these residues are part of the conserved box 
B region (Fig. 3.9). The corresponding amino acids in this region preceding box B are a 
part of the substrate binding pocket in E. coli LepB as indicated by the crystal structure 
(Paetzel et al., 1998) and modelling data (Choo et al., 2008). Furthermore, NMR 
experiments on the truncated derivative of LepB also showed that five of these amino 
acids are perturbed by substrate binding (Musial-Siwek et al., 2008b), confirming the 
interaction of these residues (in the proposed binding pockets of the enzyme) with the 
substrate. In SpsB, it is also likely that one or more of the amino acids immediately 
preceding the catalytic serine form a part of the substrate-binding pocket which can only 
be confirmed when the crystal structure becomes available.  These residues possibly also 
contribute to the correct folding and conformation of the enzyme.  
3.2 Discussion 
In this chapter, we have analyzed the activities of the full-length SpsB as well as the 
truncated derivatives using a synthetic peptide substrate which has enabled a quantitative 
comparison. Furthermore, we have studied the in vitro pH-requirement, stability and self-
cleavage of the full-length enzyme and the effect of detergents on the truncated (tr-SpsB) 
derivative.   
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The specific enzymatic activity (kcat/Km) of the full-length SpsB on this internally 
quenched decapeptide, SceD is approximately 1850 M-1s-1 which is about a hundred-fold 
higher (Table 1.1) than the reported specific activity of the same enzyme with a 
fluorogenic hendeca peptide based on the signal peptide region of maltose-binding 
protein (Zhong & Benkovic, 1998). However, the specific enzymatic activity of SpsB on 
a 13-amino acid long synthetic peptide substrate with an N-terminal fatty acid (Bruton et 
al., 2003) is over a thousand-fold (1240) higher compared the activity with the SceD 
peptide (Table 1.1). Although the length of the peptide substrate is known to influence 
activity (the longer the better), the presence of an N-terminal fatty acid in this case 
appears to contribute to the dramatic difference in specific activity. The above results 
further support the hypothesis of Brutton and co-workers (2003) on the beneficial role of 
N-terminal fatty acid in synthetic SPase substrates. 
 
The in vitro activity of SpsB has been demonstrated using two different substrates: a 
preprotein (in chapter 2) and a synthetic peptide (this chapter). Interestingly, previous 
studies on the cleavage of peptide substrates by SpsB indicated that the enzyme prefers 
basic residues at the -2 position and tolerates hydrophobic residues as well (Bruton et al., 
2003). On the other hand an acidic residue at this position results in a significantly 
reduced rate of processing by SpsB (Bruton et al., 2003). In agreement with this, both 
substrates pre-IsaA as well as the SceD peptide used in this work possess a basic residue 
(His) at the -2 position and have been processed efficiently by the enzyme. In parallel to 
this work, the -3 to +1 pattern for productive recognition and cleavage by SpsB was 
defined as (AVS)-(KHNDQSYEGLR)-A-(AESDIKL) by comparing the predicted SPase 
recognition and cleavage sites for signal peptides of proteomically identified extracellular 
proteins of S. aureus (Sibbald et al., 2006). The residues in parenthesis are indicated in 
decreasing order of frequency of occurrence. The common residues in the two substrates 
used in this work at the -3 to -1 positions and the +1 residue (Ala in case of IsaA and Ser 
in case of SceD) are underlined. These experimental results are in favour of the above 
observations made in silico. 
 
The optimum pH of SpsB (approximately pH 8) is comparable to that of Spi (S. 
pneumoniae), SipS (B. subtilis) and LepB (E. coli) which have optima of pH 8, pH 10 and 
pH 9, respectively (Paetzel et al., 1997; Peng et al., 2001a; van Roosmalen et al., 2001), in 
agreement with the catalytic mechanism. Notably, SpsB is active at a broader range of pH 
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(5-12) compared to E. coli LepB which is active from pH 7-11 (Paetzel et al., 1997). The 
pH-rate profile of SpsB did not result in a typical single bell-shaped curve which has 
been summarized in Scheme 1. Analysis of the pH-rate profile, suggests that the apparent 
pKa value of 6.6 from the ascending limb could correspond to lysine which acts as a 
general base in this class of enzymes.  It is interesting to note that this value is 2.1 pH 
units lower than that observed for LepB of E. coli (Paetzel et al., 1997) and 4 pH units 
lower than the pKa of lysine in solution.  The reason for the decreased pKa of the active-
site Lys in the SPases is not known.  It is also not clear whether the hydrophobic 
environment of the membrane contributes to this. 
 
Full-length SpsB also appears to be comparatively stable in vitro as we can observe the 
protein on CBB-stained SDS-PAA gel after a minimum of 9 days (even up to 15 days, 
data not shown) storage at 4 °C. In contrast, 90 % of the full-length LepB of E. coli, is 
degraded in 11 days at 4 °C (Talarico et al., 1991). Nevertheless, since self-cleavage is 
known to be a concentration-dependent event (as also observed during this work, data 
not shown), the self-cleavage event remains a hurdle in structure determination where 
highly pure and concentrated protein samples are required. For the in vitro assays, the 
purified enzyme was used within a couple of days or stored at -80 °C for subsequent use.  
 
The self-cleavage of SpsB obeys the (-3,-1) rule of SPasesI as confirmed by N-terminal 
sequencing and is an intermolecular event as shown by the addition of the SPase 
inhibitor arylomycin which did inhibit autolysis. Self-cleavage of SpsB occurs in the 
region around the catalytic Ser, similar to that reported for Spi (S. pneumoniae) and SipS 
(B. subtilis). In contrast, self-cleavage in LepB (E. coli) occurs in the hydrophilic domain 
connecting the two transmembrane domains at the N-terminus (Talarico et al., 1991). 
While the above observations of self-cleavage were made in vitro, self-cleavage has also 
been reported to occur in vivo in Spi.  In the case of LepB, it is believed that the enzyme 
is protected from self-cleavage in vivo due to the fact that the autolysis site and the 
catalytic site are at the opposite sides of the membrane.  This view has been supported by 
studies involving membrane-incorporated LepB where a dramatic decrease in self-
cleavage was observed (Wang et al., 2004).  
 
The detergent requirement for the tr-SpsB is surprising as most of the predicted 
transmembrane residues have been removed. The detergent-dependent activity of 
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truncated SPase was first reported for E. coli LepB (Tschantz et al., 1995).  Among Gram-
positive bacteria, a detergent-dependent activity of full-length signal peptidase has been 
reported in S. pneumoniae Spi (Peng et al., 2001a), and in three of the four SPases (SipX, 
SipY and SipZ) of S. lividans (Geukens et al., 2002).  In S. lividans, a truncated SipY 
derivative devoid of the C-terminal anchor was shown to be stimulated by detergents, 
albeit to a lesser extent compared to the full-length (Geukens et al., 2002). However, 
truncated SipS from B. subtilis was reported to have detergent-independent activity (van 
Roosmalen et al., 2001).  The effect of detergent on the truncated signal peptidase is most 
likely protein specific.  Although it is not clear at this stage, the truncated SpsB probably 
has a better conformation in the presence of detergent which could partially make up for 
the lack of the hydrophobic membrane segment.  
 
In chapter 2, we observed that the truncated derivative (tr-SpsB) lacking most of the 
transmembrane segment residues could process the preprotein substrate. In this chapter 
however, we show that despite no loss in cleavage fidelity is observed, the activity of this 
protein is 30-fold less compared to the full-length enzyme. The results highlight the 
importance of the transmembrane segment residues in the optimum activity of SpsB. 
Similar reduction in activity has been reported with truncated derivatives of LepB from 
E. coli and SipS from B. subtilis and it was also shown that these enzymes maintain their 
high in vitro cleavage fidelity (Carlos et al., 2000b). Finally, we observed that the N-
terminally truncated self-cleavage product of SpsB (sc-SpsB) is inactive, while tr-SpsB 
which has only 9 additional amino acids at the N-terminus remains active. These results 
indicate that some of the amino acid residues immediately preceding the catalytic Ser at 
the N-terminal part of SpsB sequence are essential for enzyme activity.  
3.3 Experimental procedures 
3.3.1 Specificity of the cleavage of the SceD peptide by SpsB 
For the initial tests and validation of the FRET assay with SpsB, a small amount of the 
SceD peptide was obtained [synthesized by Bockstael K], while additional substrate for 
further work was procured from custom peptide synthesis (Peptide Protein Research 
Ltd). The specificity of cleavage was confirmed as described (Bockstael et al., 2009a). In 
brief, SpsB and SceD peptide (at final concentrations of 1 µM and 500 µM, respectively) 
were incubated at 37 °C for 15 h in a total reaction volume of 40 µl. A negative control 
reaction without SpsB was included.  The reactions were stopped by the addition of 
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trifluoroacetic acid.  After centrifugation, supernatant from the samples were applied to a 
RP-HPLC column.  The resulting fractions were collected, lyophilized and subsequently 
subjected to ESI-MS analysis.  
3.3.2 FRET-based assay 
The reaction mixtures in the FRET assay contained SpsB (pretreated with protease 
inhibitor cocktail - Complete, mini, EDTA-free, Roche Diagnostics) and SceD peptide 
(dissolved in DMF) at final concentrations of 1 and 10 µM, respectively, in the assay 
buffer (50 mM Tris-HCl, pH8 with 0.5 % Triton X-100) and the reactions were carried 
out in 96-well black, clear bottom microtitre plates (Greiner bio-one) at 37 °C in a total 
volume of 100 µl.  The final concentration of DMF in the reaction mixtures was 1 %. 
The enzyme was initially pre-incubated in the buffer for 5 min at 37 °C and the reaction 
was started by the addition of the substrate.  Fluorescence intensity measurements were 
taken as a function of time using an InfiniteTM M200 automated microplate reader 
(Tecan, Austria GmbH).  The excitation and emission wavelengths used were 340 nm 
and 510 nm, respectively.  The data obtained were fitted by non-linear curve fitting on 
Origin® Pro 7.5 (Microcal) using the equation y = (A0(1-e(-kt))) + B0, to get the first order 
rate constant k = Kobs.  The specific enzymatic activity was calculated using the equation 
kcat/Km = kobs /[Enz]. 
 
The specific enzymatic activity or apparent second order rate constant kcat/Km of the full-
length and the truncated SpsB were measured using varying concentrations of the 
enzymes (freshly purified)  and a fixed concentration of the peptide substrate, wherein 
[S]<<Km (apparent).  The final concentration of the substrate was 5 µM for the full-length 
and 2.5 µM for the truncated enzyme.   
3.3.3 Activity at varying pH  
For determination of optimum pH, the in vitro preprotein processing assay was carried 
out in the following buffers of varying pH: Glycine-HCl buffer pH 2; citric acid/sodium 
citrate buffer pH 3, 4 and 5; Clark and Lubs solutions-KH2PO4/NaOH pH 6 and 7; Tris-
HCl buffer pH 7, 7.5, 8 and 8.5 and 9; glycine-NaOH buffer pH 9 and 10; carbonate 
buffer pH 10.9; phosphate buffer pH 11; hydroxide-chloride pH 12, prepared according 
to Dawson et al., 1989. 
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The pH-rate profile using the synthetic SceD peptide was measured by calculating the 
kcat/Km values of the full-length enzyme incubated in buffers with varying pH.  It should 
be noted that the freshly purified enzyme was stored at 4 °C for ~24 h prior to use.  The 
reactions were carried out in a total volume of 100 µl with 1 µM final concentration of 
the enzyme.  After pre-incubation of the reaction mixture for 5 min at 37 °C, the peptide 
substrate was added to obtain a final concentration of 5 µM ([S]<<Km).  This was 
followed by measurement of fluorescence intensity as a function of time.  The specific 
activity obtained was plotted as a function of pH using Eqn. 1 (see 3.1.2).  
3.3.4 Stability at different temperatures 
Purified SpsB (pre-treated with a general protease inhibitor) was aliquoted into 
polypropylene microfuge tubes (20 µl in each) and allowed to stand at different 
temperatures (27 °C, 37 °C or 4 °C) for a maximum of 9 days.  All samples were initially 
stored at -80 °C and collected in the reverse order for incubation meaning that 9th day 
samples were incubated first followed by the 6th and the 4th and finally, 0 h sample was 
removed just before preparing the samples for loading on gel.  For stability of SpsB in 
the presence of the inhibitor arylomycin A2, 18 µl of purified full-length SpsB (31 µM 
stock concentration) was incubated with 2 µl arylomycin A2 (2 mM stock concentration 
in DMSO) or DMSO (control) at 37 °C for 7 days.  To these samples, 4 µl of 6x SDS-
PAGE sample loading buffer was added and incubated for 10 min at 37 °C.  The 
proteins were separated on 12.5 % w/v SDS-PAA gels followed by staining with CBB. 
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UFigure 4.1: Time-course FRET assay with SpsB. U Reaction mixtures containing different 
concentrations of SpsB (2 to 10 µM) in assay buffer were incubated for 5 min at 37 °C. Reactions 
were started by adding the synthetic SceD peptide (5 µM) and fluorescence intensity was 
measured as a function of time.  
 
Chapter 4: Development and validation of in vitro inhibition 
assays for SpsB 
In this chapter, we have focused on the standardization and evaluation of the SpsB-
FRET assay described in chapter 3, as the primary assay for screening compounds that 
inhibit SpsB in vitro. Given the fact that the synthetic peptides are rather poor substrates 
for the SPases, we also set out to validate the preprotein processing assay, described in 
chapter 2. Although low-throughput this secondary assay is more relevant. It should be 
noted that for the inhibition assays, only full-length SpsB and not truncated derivative(s), 
was used. 
4.1 Results 
4.1.1 Set-up and validation of the SpsB-FRET (primary) assay for 
compound screening 
4.1.1.1 SpsB activity as a function of time and enzyme concentration 
Varying concentrations of the full-length SpsB (0.1 to 2 µM final concentration) and 
fixed concentrations of the SceD peptide substrate (5 and 10 µM final concentration) 
were tested in the FRET assay, described in chapter 3. A linear increase in signal was 
observed for all concentrations tested during the time-course of the assay (Figure 3.3, 
chapter 3). The linear regression analysis revealed R2 values from 0.981 to 0.992 for the 
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concentrations tested (0.2 to 1 µM) over a span of 870 seconds (data not shown). 
Complete processing as evidenced by no further increase in fluorescence intensity was 
achieved faster at higher enzyme concentrations. The complete processing of the 
substrate typically resulted in a 6-fold increase in signal from that of the initial value 
(Figure 4.1). Based on these results the enzyme concentration was fixed to a final 
concentration of 1 µM, while that of the substrate was fixed to 10 µM (where [S] Km ; 
predicted Km value for the synthetic peptide is >100 µM) for initial studies. It should be 
noted that 5 or 2.5 µM (final concentration) of the substrate has also been used in some 
cases as indicated.  
4.1.1.2 Initial velocity phase 
It is important to ensure that the assays are conducted during the initial velocity phase in 
order to identify competitive inhibitors. The initial velocity is the best measure of enzyme 
reaction rate and this phase is most sensitive to reversible inhibitors (Copeland, 2005). 
The measurements were immediately stopped 30 minutes after the addition of the 
substrate and the data corresponding to the initial velocity phase were analyzed.  
4.1.1.3 In vitro inhibition of SpsB in the presence of SPase inhibitor arylomycin A2 
As part of the validation of the FRET assay, the SPase inhibitor arylomycin A2,was added 
to the reaction mixture. In the presence of the inhibitor, no increase in fluorescence 
intensity was observed during the time-course of assay (Fig. 4.2a), confirming that the 
peptide remains uncleaved, when the enzyme activity is inhibited.  A dose-dependent 
response to arylomycin A2 was plotted (Fig. 4.2b) and the IC50 of the inhibitor against 
SpsB was found to be 1 µM (0.82 µg/ml). Additionally, the protocol for this assay and 
the enzyme were used for testing a set of rationally designed lipopeptides of which the 
best compound, a peptide aldehyde inhibitor was shown to have an IC50 of 0.09 µM 
against SpsB (Buzder-Lantos et al., 2009).   
4.1.1.4 Microplate uniformity test 
Prior to compound screening, it is important to test plate uniformity or signal variability 
between individual wells of a microplate. For this purpose, positive controls (with 
enzyme, substrate and DMSO in assay buffer) giving the maximum signal and negative 
controls (with substrate and DMSO in assay buffer but not the enzyme) giving minimum 
or the background signal were set up in a 96-well plate. The final concentrations were 1 
µM of the enzyme and 2.5 µM of the substrate in a total volume of 100 µl. DMSO was 
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(a) 
 
 
(b) 
 
UFigure 4.2: Inhibition of SpsB activity by arylomycin A2 in the FRET assay.U (a) Time-
based scan: SpsB (1 µM final concentration) was incubated without or with arylomycin A2 (10 
µM final concentration) for 15 minutes at 37 °C followed by the addition of SceD peptide (5 
µM final concentration).  Fluorescence intensity was measured as a function of time. (b) Dose-
dependent response:  The assay was carried out with SpsB (1 µM final concentration) 
incubated with different concentrations of arylomycin A2 (from 20 µM to 0.0244 µM) followed 
by the addition of the peptide (10 µM final concentration).  Percent SpsB activity was plotted as 
a function of inhibitor concentration (using curve expert 1.3: 
http://userpages.xfoneusa.net/~dhyams/cmain.htm) to obtain the IC50 value arylomycin A2 
against SpsB.  
present at a final concentration of 10 %. All additions were done manually using single 
channel pipettes and the readings were taken immediately after the addition of the 
peptide substrate. Upon data analysis it was confirmed that the readings are consistent 
throughout the plate, with a minor but negligible difference between the ends and center 
of the plate (Figure 4.3; Table 4.1). Subsequently, multichannel and repeat pipettes were 
used for preparing reaction mixtures which minimizes the handling times and improved 
the uniformity of the signals (data not shown). 
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UFigure 4.3: Plate uniformity testU. The positive and negative control reactions (with and 
without the enzyme, respectively) were set up in a single microtitre plate in the format 
indicated. The data corresponding different parts of the plate are indicated. The colour lines 
indicate samples from different wells. The signal remains constant over time in control 
reactions compared to a progressive increase in signal intensity in the test samples.  
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4.1.1.5 DMSO compatibility 
Since compounds to be tested are routinely dissolved in DMSO, solvent compatibility in 
the assay was also tested. It was observed that the assay is compatible with DMSO up to 
10 % (v/v) (data not shown) and therefore the reactions were carried out at a maximum 
of this concentration of the solvent. 
4.1.1.6 Inter-plate and inter-day variation 
The assays were carried out for three consecutive days to check for inter-plate as well as 
for inter-day and intra-day variation. The analysis showed that the variations between 
these data sets were negligible and the assay quality was satisfactory (data not shown). 
The quality of the enzyme (temperature and duration of storage) is important for 
maintaining the assay quality. As discussed in chapter 3, even storage for a long period at 
4 °C decreased the activity of the enzyme. Freshly purified enzyme was stored at 4 °C 
and used within a period of three days. 
4.1.2 Set-up and validation of the SpsB-preprotein processing 
(confirmatory) assay for testing positive compounds  
The SPase inhibitor arylomycin A2 was also tested in the preprotein processing assay, 
discussed in chapter 2. In the presence of the SPase inhibitor, the substrate pre-IsaA 
remained unprocessed by SpsB (Figure 4.4).  Similarly, another SPaseI inhibitor (5S,6S)-
6-[(R)-acetoxyethyl]-penem-3-carboxylate (a kind gift from Glaxo Smith Kline, Harlow, 
UTable 4.1: Signal variation within a microtitre plate 
 
Area in the 
microplate 
Slope 
(average) 
Standard 
deviation 
Slope 
(average) 
Standard 
deviation 
Negative 
control 
Negative 
control 
Positive control Positive control
Rows -0.01396 0.001111 0.191033 0.020282 
Columns -0.01684 0.002516 0.208807 0.064613 
Ends -0.01409 0.00055 0.164554 0.02845 
Center N/A N/A 0.218694 0.014791 
Entire plate -0.01497 0.002221 0.195133 0.037028 
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UK) could inhibit preprotein processing by SpsB (data not shown). These observations 
confirmed the suitability of the in vitro assay for confirming hits obtained from the 
primary assay. Additionally, the presence of DMSO up to 10 % (v/v) or the presence of 
a non-SPase inhibitor (up to 5 mM final concentrations) did not affect preprotein 
processing by SpsB (data not shown).  
 
4.1.3 Manual screening and further analysis of compounds  
Manual screening was carried out in 96-well plates with at least two positive and negative 
controls. The standard protocol involved the addition of enzyme and the compounds (at 
1 µM and 200 µM final concentrations respectiveley) to the assay buffer followed by a 
brief incubation and the addition of the SceD peptide substrate (10 µM final 
concentration). The fluorescence intensity was measured over a period of 30 min. The 
reactions were carried out in a total volume of 100 µl at 37 °C. The percent activities 
relative to the positive control reactions were calculated. The threshold for hit calling was 
set to 60 % inhibition of the enzyme activity. Around 6,200 compounds obtained from 
different sources were screened manually in the FRET assay against SpsB. The 
compounds tested consisted of synthetic compounds (received from the lab of Prof. Dr. 
Erik Van der Eycken, K.U.Leuven), small molecules from the chemical compound 
libraries of the Rega Institute and Center for Drug Design and Discovery (CD3), 
rationally designed peptides based on modeling into the active site of LepB (received 
from Prof. Dr. Joost Schymkowitz, VUB, Brussels) and small molecules based on virtual 
screening using the crystal structure of LepB [received from Center for Innovation and 
Stimulation of Drug Discovery (CISTIM), Leuven]. 
 
 
UFigure 4.4: Preprotein processing by SpsB blocked by arylomycin A2 U SpsB and pre-IsaA 
(1 and 10 µM final concentrations, respectively) were incubated without and with arylomycin 
A2 (200 µM final concentration) for 15 h at 37 °C.  The proteins were separated on 12.5 % 
(w/v) SDS-PAA gels and analyzed by Western blotting and chemiluminescent detection. 
Lane 1, molecular weight marker; Lane 2, pre-IsaA processing by SpsB; Lane 3, pre-IsaA 
processing blocked by arylomycin A2. 
50 kDa
37 kDa
25 kDa
1      2      3
Pre-IsaA
IsaA
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The primary screen with the FRET assay did not result in any compound reaching the set 
threshold (>60 % inhibition of SpsB activity). The compounds obtained from virtual 
screening also did not significantly inhibit SpsB or E. coli LepB in the FRET assay. 
Nevertheless, we observed that most of the compounds from in silico screening were able 
to inhibit E. coli LepB in vitro to a greater extent in comparison with SpsB. We found that 
a number of compounds interfered with fluorescence. Approximately 1 % of the total 
number of compounds screened could not be interpreted correctly due to this reason, 
and hence, were tested in the preprotein processing assay. None of these compounds did 
inhibit preprotein processing by SpsB. They were also subsequently ruled out as potential 
inhibitors after confirmation of their interference in the assay by testing them in the 
absence of the enzyme but in the presence of the peptide substrate.  
 
In order to possibly minimize the interference of the test compounds in the FRET assay, 
a new peptide with an identical sequence as the SceD peptide, except for an additional C-
terminal Lys and with a new FRET pair (5-FAM/5-TAMRA), was procured. The 
additional Lys at the C-terminus of the peptide was required to attach the 5-TAMRA to 
the side chain amine. Unfortunately, the peptide was not recognized and cleaved by SpsB 
in the FRET assay using excitation and emission wavelengths of 485 and 520 nm, 
respectively. However, the peptide could be non-specifically cleaved by proteinase K as 
evidenced by a significant increase in fluorescence intensity compared to a control 
without the peptide.  
4.2 Discussion  
For a biochemical assay with a potential high-throughput screening application it is 
necessary to ensure reproducibility and reliability of the output data. This chapter focuses 
on the pre-screen and in-screen evaluation of the SpsB-FRET assay. The initial 
conditions for the FRET assay were standardized and the in vitro inhibition of SpsB in 
this assay was first demonstrated using the known SPase inhibitor arylomycin A2. Pre-
screen evaluation included the study of signal variation within a microplate, storage and 
compatibility of the assay components and comparison of inter-day and intra-day data. 
 
After the initial tests were positive, manual screening was commenced with compounds 
(small molecules/peptides) from different groups. The criterion for selecting a 
compound from the primary screen was set initially to 60 % inhibition of SpsB in the in 
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vitro assay. The maximum inhibition that could be achieved was 40 % and given the high 
concentration of the inhibitor used in the assay, this activity was not considered 
significant. One of the shortcomings of the FRET assay is its incompatibility with 
compounds that are autofluorescent or those that interfere with fluorescence. Many such 
compounds were observed and those that could not be clearly distinguished (61 
compounds i.e., 1 % of the total compounds tested) were analyzed in the preprotein 
assay but none of these compounds were inhibitory. However, it should be noted that 
the preprotein assay is much more stringent than the FRET assay as the affinity of the 
enzyme for the preprotein is much higher than for a short peptide. A much higher 
inhibitor concentration (at least a 100-fold higher concentration compared to that used in 
the FRET assay) is required for inhibition of preprotein processing by SpsB. Although it 
is possible to distinguish a potent inhibitor from a non-inhibitor in the preprotein assay, 
it is difficult to analyze weak inhibitors in this assay, since the assay is semi-quantitative at 
best. The FRET assay can potentially identify weak inhibitors as long as they do not 
interfere with fluorescence. To find out if the problem of fluorescence interference by 
the compounds could be lowered, a peptide substrate with a new FRET pair was 
obtained. Although theoretically this should not affect the behaviour of the substrate, it 
could not be processed by SpsB. The reason for the inability of SpsB to process this new 
peptide remains unclear. It might be a result of steric hindrance caused by the dye which 
is attached to the side chain of Lys. In contrast, the EDANS/DABCYL peptide 
substrate has the FRET pair in the main chain of the peptide.  
 
Given that the crystal structure of SpsB is not available, rational approaches for 
designing/finding effective inhibitors are pretty limited. There is less than 30 % sequence 
identity among SpsB and E. coli LepB which makes it difficult to come up with a 
homology model of SpsB based on the known crystal structure of LepB. Among the 
compounds screened against SpsB, a set of 124 compounds were based on in silico 
screening of compounds in the active site of E. coli LepB. With the limited number of 
such compounds tested in the FRET assay, we did not see significant inhibition of SpsB 
or LepB in vitro, although we observed that most compounds were comparatively better 
against E. coli LepB. This again implies that there are subtle differences among the two 
signal peptidases. Nevertheless, this approach holds potential in finding a broad 
spectrum inhibitor. 
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Despite screening over 6,000 compounds we could not come up with a single potent 
inhibitor. This in fact is not very surprising as we can see from the literature that SPasesI 
have been difficult targets as far as finding effective inhibitors are concerned. As already 
mentioned, the type I signal peptidases are resistant to the general protease inhibitors 
against the four different classes of proteases. Ever since the SPasesI were proposed as 
targets more than a decade back, efforts from different groups resulted in only the few 
potent inhibitors that have been described (chapter 1; Table 1.2). These inhibitors were 
obtained using two different approaches, one of which is the classical approach by 
rational modification of lipopeptides based on preprotein sequence data. The second is 
the screening approach to possibly obtain new classes of inhibitors, which is also the 
focus of this and the preceding chapter. A fluorimetric assay (similar to the one described 
in this chapter) was used by a group at Eli Lilly and company for high-throughput 
screening of 50,000 pre-fractionated natural samples against signal peptidase S. 
pneumoniae, Spi (Kulanthaivel et al., 2004). This work by Kulanthaivel and co-workers led 
to the identification of a single sample with reproducible activity – the lipoglycopeptide 
inhibitors (see chaper 1). There is no literature available on how the inhibitory activity of 
arylomycins against the SPases was found as the first report on this inhibitor was the 
crystal structure of 2-75 SPase in complex with the arylomycin A2 (Paetzel et al., 2004). 
It is not clear whether the structural similarities between lipoglycopeptides and 
arylomycins subsequently led to the antibacterial activity of arylomycins being attributed 
to their inhibition of SPases. Another pharmaceutical company where extensive studies 
on SPase inhibitors were undertaken is SmithKline Beecham Pharmaceuticals (now 
GSK) (Harlow, Essex, UK). Their work started when very little was known about the 
catalytic centre of SPasesI and later when evidence started accumulating in favour of 
SPasesI being a serine protease utilizing a Ser/Lys catalytic dyad mechanism (around 
1992-1993), they began screening a range of compounds from a large in-house collection 
of beta-lactam containing compounds (Allsop et al., 1995). Their compound collection is 
said to have consisted of inhibitors developed against bacterial beta-lactamases, 
transpeptidases and carboxypeptidases; enzyme families that are also based on a 
serine/lysine catalytic dyad (Allsop et al., 1995). This led to the discovery of the 5S 
penems inhibitors and their optimization work culminated in the identification of the 
compound allyl (5S,6S)-6-[(R)-acetoxyethyl]-penem-3-carboxylate (Black and Bruton, 
1998). 
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Comparatively, the number of compounds screened here (this chapter) and random 
screening is indisputably a matter of chance. However, we ruled also out the possibility 
that the low success rate might just be a reflection of the assay quality by assessing the 
reliability of the FRET assay based on the method described by Zhang and co-workers 
(Zhang et al., 1999). In addition, we have demonstrated in vitro inhibition of SpsB in the 
FRET assay using two different inhibitors under the same conditions described in this 
chapter.  Apart from the random screening approach it was also our intent to try and 
obtain structural data on SpsB to be able to carry out virtual screening and subsequently 
test the interesting compounds in vitro. The purified full-length SpsB and the truncated 
active and inactive SpsB were provided for crystallization trials to Prof. Dr. R. Loris 
(VUB, Brussels), under a collaborative project. The crystallization trials so far have been 
unsuccessful due to problems of instability of the active forms and aggregation observed 
in the truncated inactive mutant of SpsB.   
4.3 Experimental procedures 
4.3.1 In vitro inhibition of pre-IsaA processing by SpsB  
For the preprotein assay in the presence of inhibitor, arylomycin A2 (200 µM final 
concentration) was added to a reaction mixture containing SpsB (1 µM final) in the assay 
buffer and the samples were incubated for 5 minutes at 37 °C followed by the addition of 
pre-IsaA (10 µM).  After incubation for 15 h at 37 °C, the reactions were stopped by 
addition of 4 µl of 6 x SDS-PAGE sample loading buffer.  The proteins were separated 
by SDS-PAGE using 12.5 % (w/v). Western blotting and immunodetection were carried 
out as described in chapter 2, section 2.3.7.      
4.3.2 FRET assay with the inhibitor arylomycin A2 : 
The inhibitor arylomycin A2 (Baselia Pharmaceutica) was dissolved in DMSO and diluted 
to obtain different stock concentrations.  For the in vitro assay, the reaction mixtures 
containing SpsB (1 µM final concentration) with different concentrations of arylomycin  
A2, were incubated in the assay buffer for 15 minutes.  The final concentration of DMSO 
in each reaction mixture was 2 %.  The fluorogenic synthetic peptide SceD (5 or 10 µM) 
was added and fluorescence intensity was measured (using excitation and emission 
wavelengths of 340 and 510 nm, respectively) as a function of time.  For dose-dependent 
response and determination of IC50, ten different concentrations of arylomycin A2 were 
used (two-fold serial dilutions starting from 12.5 to 0.0244 µM final concentration) and 
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the substrate concentration was 10 µM (final).  Percent inhibition was calculated using 
the equation [(1-(vi/v0)] x100, where vi is the initial velocity in the presence of inhibitor, 
v0 is the initial velocity in the absence of inhibitor. The IC50 value was determined by 
fitting the percentage inhibition versus inhibitor concentration using the MMF model for 
sigmoidal curve (see following equation).  
                                                        
d
d
ab cxy
b x
                                          Equation 2 
 
4.3.3 SpsB-FRET assay for compound screening 
The assay was carried out in black transparent bottom 96-well microplates (Greiner) in a 
total volume of 100 µl. The full-length SpsB premixed in the assay buffer was dispensed 
(90 µl of 1.1 µM stock of the enzyme) in each well (except for the negative control) 
followed by the addition of 10 µl of the test compound (or DMSO in case of the positive 
control). To the negative control reactions, 90 µl of buffer without the enzyme was 
added, followed by the addition of DMSO. The reactions were incubated for 5 minutes 
at 37 °C followed by the addition of 1 µl of the SceD peptide (1 mM stock in DMF) and 
fluorescence intensity measurement (using excitation and emission wavelengths of 340 
and 510 nm, respectively; time interval of 30 sec for a total number of 65 cycles). The 
fluorescence intensities obtained were first scaled to zero. Next, the end values (final 
measurement at 30 min minus the initial measurement) for each compound was 
converted to percent activity with respect to the positive control (without the inhibitor). 
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Chapter 5: High-throughput screening of compounds against 
SpsB and analysis of possible hits 
In this chapter, the transfer of the SpsB-FRET assay from the research lab to a high-
throughput screening center is described. The assay transer was carried out from the 
laboratory of Bacteriology, Rega Institute, K.U.Leuven to CISTIM, Leuven, in close 
collaboration with CD3, K.U.Leuven. The process of assay transfer towards automation 
requires a pre-assessment of the consistency and quality of data that can be obtained. To 
this end, possible modifications were made to the existing protocol and the assay was 
fine-tuned with the input from ing. Hugo Klaassen (Director, high-throughput screening 
facility, CISTIM). 
5.1 Results 
5.1.1 Assay transfer 
Inter-day as well as intra-day data were obtained from the FRET assay carried out during 
a two-day period. The assays were carried out in 384-well plates in the same format as 
that used for the final screening (described in 5.1.3), except that it was done manually. 
Analysis of data indicated that the assay was reproducible and consistent (data not 
shown). The process of automation was carried out in steps starting with four 384-well 
plates per day till up to twenty four 384-well plates per day.  
5.1.2 SpsB purification for HTS 
For high-throughput screening of the compounds, SpsB was purified in large quantities 
(to cover for 50,000 data points), pooled, aliquoted and stored at -80 °C until use. The 
enzyme was not subjected to freeze and thaw cycles and aliquots once drawn from -80 
°C were maintained at 4 °C until its use on the same day. The purity of SpsB was 
assessed by SDS/PAGE followed by CBB staining. On an average, the concentration 
amounted to approximately 13 µM or 0.3 mg/ml which was statisfactory for the in vitro 
assay.  
5.1.3 Set-up of compound library screening  
The full-length SpsB (0.25 µM), the test compound (10 µM) and lastly the substrate (5 
µM) at the final concentrations indicated were added to the assay buffer. The total 
volume of each reaction mixture was 50 µl and the final concentration of DMSO was 2 
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UFigure 5.1: Assessment of assay quality.U Each microplate for compound screening contained 
38 positive controls (SPase inhibitor) and 38 negative control (DMSO) reactions. Z’ value and 
signal-to-background ratio for each plate was obtained as described (see text) 
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% (v/v). Fluorescence intensity was measured at a single, fixed time point, 45 min after 
the addition of the substrate. Fixed-time point measurements also significantly increased 
the number of compounds that could be tested in comparison with the time-course 
assays. Attempts to stop the reactions after 45 minutes for end-point measurements did 
not prove to be successful (data not shown). The reactions were carried out at RT (22 
°C). We did not observe significant difference resulting from running the assay at either 
37 °C (previously used) or at 22 °C (data not shown). Reactions containing DMSO but 
without the test compounds served as negative controls while those containing the 
peptide aldehyde inhibitor (Buzder-Lantos et al., 2009) served as positive controls in the 
assay. Raw data were converted into percent inhibition (PIN), which is given by (1-
(sample-µC+ )/(µC-- µC+))*100, where µC+ and µC- are the means of positive and negative 
controls, respectively. Inter-day data were obtained from independent experiments 
carried out on two days using this adapted protocol and analyzed before assay transfer. 
Analysis and final validation of the assay quality is described below. 
5.1.4 Quality of the screen 
The assay was calibrated using the peptide aldehyde inhibitor. Each 384-well plate 
contained 32 positive controls with the SPase inhibitor and 32 negative controls without 
compound but with DMSO. The quality of data obtained from screening was assessed by 
calculating the Z’ factor (Zhang et al., 1999) using the formula 
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                            Z Prime or Z’ = 
 
Where, C+ and C- are standard deviations of positive and negative controls, respectively 
while µ C+ and µ C- are the means of positive and negative controls respectively. According 
to Zhang and co-workers, for an assay to be considered good for high-throughput 
screening the Z’ factor has to be ≥0.5. Prior to assay transfer, manual testing using the 
384-well format resulted in an average Z’ factor of 0.65. The analysis of the data quality 
from the SpsB inhibitor screening is summarized in (Fig. 5.1). Also indicated in Fig. 5.1 is 
the signal-to-background ratio denoted as S/B (=mean signal/mean background) which 
is another expression that is also used to indicate the quality of an assay. As seen in the 
figure, the Z’ factor during screening remained ≥0.5 with an average Z’ factor of 0.73 for 
the entire screen, indicating that the assay is robust.  
5.1.5 Screening results and follow-up tests 
An entire library of compounds from the Centre for Drug Design and Discovery (CD3) 
library compounds (25,621 in total) was screened. This library contains a wide variety of 
compounds, selected from an original 5 million compounds. Molecules were obtained 
from various sources worldwide after applying various filters including the Lipinski rule 
and some filters used by pharmaceutical companies to eliminate compounds that are 
toxic or poorly absorbed. The compounds from CD3 that were screened manually (from 
the compound library and those based on in silico screening data) were re-screened along 
with the rest of the compounds. Apart from the CD3 library, a set of 182 compounds 
were also screened from the chemical compound library of the Rega institute. The 
compounds that interfered with fluorescence (approximately 1 %) were not considered in 
the test. The final threshold for hit calling was set to >25 % inhibition. The three most 
active compounds were re-confirmed in an independent experiment and analyzed 
further. 
5.1.5.1 Dose-response for active compounds  
Dose-dependent response was observed against S. aureus SpsB with IC50 of 36 µM 
(JRD2191), 51 µM (JRD2189), 34 µM (CL018090) for the active compounds (codes 
mentioned in brackets) and IC50 of 0.23 µM for the positive control (peptide aldehyde). 
c+ c-
c+ c
(3 +3 )1
- 
   
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UFigure 5.3: Analysis of the hits in the preprotein processing assay.U The preprotein assay was 
set up with the following components at final concentrations indicated between brackets: pre-
IsaA (5 µM), SpsB (0.25 µM), test compounds or known inhibitor (500 µM) and incubated for 15 
h at 37 °C. The proteins were separated on SDS/PAA gels and analyzed by western blot followed 
by chemiluminiscent detection. Two negative controls (DMSO and a compound that does not 
inhibit SpsB activity) and two positive controls (peptide aldehyde and arylomycin A2) were 
included. 
 
UFigure 5.2: Dose-response curves for selected active compounds in the SpsB-FRET 
assay U. The SpsB-FRET assay was repeated with the selected active compounds at varying 
concentrations from 200 µM (diluted two-fold) to 0.39 µM. Percent inhibition was plotted in 
function of compound concentration. Peptide aldehyde inhibitor was used as the positive 
control. 
 
5.1.5.2 Preprotein-processing assay  
The preprotein processing assay was carried out using different concentrations of the test 
compounds (100 µM, 200 µM, 500 µM, 1 mM and 5 mM) and with appropriate controls.  
The concentration of the enzyme and the substrate were the same as those used in the 
SpsB-FRET assay. Unfortunately, the selected active compounds did not inhibit 
preprotein processing (see Fig. 5.3) and hence cannot be regarded as potent inhibitors as 
such.  
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UFigure 5.4: Test compounds with the peptide substrate U- The compounds that were active 
in the SpsB-FRET assay were retested in the absence of the enzyme. Fluorescence intensity was 
measured for each of the compound wells containing a different concentration of the test 
compounds.  
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5.1.5.3 FRET assay with E. coli lepB  
The three active compounds (JRD 2189, JRD 2191 and CL018090) behaved similarly 
showing a dose-dependent inhibition of E. coli SPase activity in vitro (data not shown). 
The slope values obtained from the progress curves of the reaction, correlated directly 
with the concentration of the active compounds. An increase in concentration of the 
compound resulted in lower slope values. 
5.1.5.4 Interference with fluorescence 
During further analysis, it was observed that two of the active compounds, when present 
at high concentrations, (>100 µM) actually quenched fluorescence to a certain extent 
(Fig. 5.4). This was confirmed by running the assay in the presence of the peptide 
substrate alone without the SPases (SpsB or lepB). JRD 2189 was the only compound 
that was effective against E. coli SPase and did not interfere with fluorescence. 
5.1.5.5 Antibacterial activity test 
Antibacterial susceptibility tests against S. aureus and E. coli were not positive (up to 500 
µg/ml) for these selected compounds. 
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5.2 Discussion 
In this chapter, we have optimized the SpsB-FRET assay for automated high-throughput 
screening of potential SpsB inhibitors. The screening protocol was modified to improve 
efficiency and make it economically feasible. The changes include a decrease in the 
concentration of the assay components, a reduction in the total reaction volume, a 
change in the microplate format, the use of a SPase inhibitor as positive control, a change 
in assay temperature (RT) and finally a fixed time-point measurement. Peptide aldehyde 
inhibitor was preferred over arylomycin as positive control as the former does not 
interfere with fluorescence. Arylomycin A2 interferes with fluorescence in the SpsB-
FRET assay to a certain extent, especially at higher concentrations. Nevertheless, its 
inhibitory activity against SpsB is very clear as the fluorescence intensity of the reaction 
mixture remains largely unchanged during the time-course of the FRET assay. We have 
shown that the assay is robust (Z’ value of 0.73) and suitable for screening chemical 
compound libraries. It is now possible to screen more than 10,000 compounds per day. 
About 27,000 compounds were screened which include the entire CD3 library and a few 
others (~260 compounds from Rega library and a few compounds selected based on 
virtual screening data). None of the hit compounds analyzed so far were good enough to 
be used directly. The hit compound JRD2189 could be further analysed by 
computational docking of the molecule into the active site of E. coli SPase. Although this 
compound is not very potent, it could serve as a starting point for further modifications.  
 
Compounds interfering with fluorescence are not compatible for high-throughput 
screening using the FRET assay since the assay is based on fixed time-point 
measurements which are compared with controls. Such compounds were treated as 
outliers and eliminated from further analysis. At the moment, it is difficult to test such 
compounds rapidly. In future, it might be interesting to run a parallel screen on a Biacore 
3000 instrument (or higher). This approach of parallel testing for inhibitory activity in the 
FRET assay as well as analysis of the affinity of the compounds for the immobilized 
enzyme on a Biacore system could possibly increase the number of compounds that can 
be tested. If any of the autofluorescent compounds show good in vitro affinity for the 
enzyme, they can be tested in the preprotein processing assay.  In addition, the dual 
approach could facilitate better interpretation of low-affinity inhibitors. In the present 
set-up, although the FRET assay can fish out low-affinity inhibitors (as long as they do 
not interfere with fluorescence) the preprotein assay might possibly eliminate these. We 
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also analyzed the selected active compounds against E. coli LepB in the FRET assay to 
partly address the problem of validating these inhibitors. For this, however, the inhibitor 
has to have a broad specificity to be able to inhibit both enzymes. The active compound 
JRD2189 could inhibit both the SPases to a limited extent in vitro. However, it remains to 
be seen whether the compound could be modified further based on modelling data.  
 
The hit rate in the FRET assay has been disappointingly low with the small molecule 
screening, although it might be too early to conclude that small molecules are not ideal 
candidates for this target. However, the prospects for pursuing this line of work remains, 
with several interesting possibilities. For example, it might be interesting to test natural 
compounds produced by certain micro-organisms in order to survive in their natural 
environment (secondary metabolites). Such compounds have been indispensable in the 
area of antibacterial drug discovery. Arylomycins and lipoglycopeptide inhibitors of signal 
peptidases are examples of this type of molecules. Natural products are proposed as 
optimal candidates for antibacterial drug screening as they have optimal cellular 
penetration and privileged structures to interact with finite structural spaces in protein 
folds (Devasahayam et al., 2010). In recent years, another school of screening that has 
been pursued in target-based drug discovery process is the fragment-based method for 
identifying lead compound(s). This involves screening fragments or scaffolds which are 
of lower molecular weight (MW < 200 Da) than the molecules that are typically found in 
high-throughput compound collections.  Once fragment hits are found to act against a 
target protein, they are then grown, linked or decorated to larger, drug-sized compounds 
often using structure-guided medicinal chemistry (Jhoti, 2005). The fragments often 
exhibit lower affinities (µM to mM) but then fragment-to-lead activity typically allows the 
affinity to be increased by 3-5 orders of magnitude after synthesis of less than 100 
compounds (Jhoti, 2005).  The assays developed in this work should enable further 
screening with different kinds of compound libraries. Additionally, if and when the 
crystal structural of SpsB becomes available, in vitro screening could be complemented 
with virtual screening to improve the chances of obtaining hit compounds.  
5.3 Experimental procedures 
5.3.1 Assay components (Preparation and storage) 
Assay buffer (50 mM Tris HCl pH8 with 0.5 % Triton X-100) was prepared fresh for 
every batch of screening and kept at RT. Compounds from the CD3 library were 
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dissolved in 100 % DMSO to a 5 mM concentration using an automated liquid handling 
system (Evo-200, Tecan) and diluted (1:25) in assay buffer (to obtain a 200 µM working 
solution of the compound) for immediate use while the rest was stored at -20 °C. The 
compounds from Rega Library were prepared as 10 mM stocks in DMSO, dispensed 
manually into 96-well storage plates and stored at -20 °C O/N. The subsequent dilution 
in assay buffer (to obtain 200 µM) was carried out at CISTIM prior to screening. The 
stock solution (1 mM) of SceD peptide substrate was prepared in DMF starting from the 
lyophilized powder stored at -20 °C, or prepared a day in advance and stored as aliquots 
at -20 °C. The SPase inhibitor peptide aldehyde was obtained commercially 
(PeptideSynthetics, Peptide Protein Research Limited, UK). SpsB was purified as 
indicated in 2.3.4 (chapter 2) in large batches. After analysis by SDS/PAGE followed by 
CBB staining the purified fractions were pooled, quantified, aliquoted and stored at -80 
°C.  
5.3.2 Compound screening (standardized protocol) 
The standardized tests were carried out in 384-well full black plates (Greiner). The 
enzyme was pre-mixed in the assay buffer and 42.5 µl of this solution was dispensed in 
each well using a plate dispenser (Xrd- 384, fluidx). The first and last two rows in the 
384-well plate were used for control reactions. To the top half of the first and last two 
rows, 2.5 µl of DMSO was added. To the bottom half of the first and last two rows 2.5 µl 
of peptide aldehyde inhibitor (200 µM stock in assay buffer) were added manually. Next, 
2.5 µl of the test compounds (200 µM in assay buffer) was added to each well and mixed 
using a liquid handling robot. Finally, 5 µl of the substrate, freshly diluted in assay buffer 
(50 µM working solution), was added to each well. The plates were centrifuged at 314 x g 
for 1 minute followed by incubation in dark (as the substrate is photosensitive) for 45 
minutes at 22 °C. Fluorescence intensity was measured (during the initial velocity phase) 
45 minutes after the addition of the substrate, using a microplate reader (Envision 2104, 
Perkin Elmer). The raw data obtained from screening was converted to percent 
inhibition using Pipeline Pilot software (Accelrys). 
5.3.3 Dose-response 
The stock solutions of selected compounds were prepared freshly and diluted (two-fold) 
in 100 % DMSO. The concentrations of the stock solutions ranged from 10 mM to 
0.0195 mM for the compounds and 1 mM to 0.00195 mM for the peptide aldehyde 
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inhibitor. The assay was carried out as indicated above with positive controls in the first 
and last two columns. The data analysis was carried out using Graphpad prism software. 
5.3.4 Additional tests 
5.3.4.1 FRET assay with E. coli lepB  
The plasmid carrying E. coli SPase encoding gene was obtained and LepB was 
overproduced and purified as described (Bockstael et al., 2009a). The purification 
protocol was essentially the same as that for the full-length SpsB except that the Ni2+-
NTA column was washed twice with buffer containing 20 mM imidazole prior to elution 
with a buffer containing 250 mM imidazole (omitting the previous step of elution with 
buffer containing 100 mM imidazole). The FRET assay was set up and dose-response 
studies with the compounds of interest were carried out as described for SpsB.  
5.3.4.2 Preprotein assay 
The assay was carried out as described in chapter 4 except that for each compound 
multiple concentrations were used. 
5.3.4.3 Antibacterial activity tests 
Antimicrobial susceptibility testing against E. coli DH5 alpha and S. aureus ATCC 65388, 
was carried out according to standard procedures using the broth microdilution method 
in LB medium (NCCLS, 2003). 
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Chapter 6: General discussion and future perspectives 
S. aureus may occur as a commensal, but is also a pathogen responsible for a wide array of 
infections. The problem of multi-drug resistance in S. aureus is a reason for the growing 
concern in the medical community. Given the emergence of resistant strains in 
community and hospital environments, an urgent need for new classes of antibiotics has 
surfaced. This has led to an interest in new antibiotic target sites in the bacteria for 
possibly minimizing cross-resistance to any new drug. The type I signal peptidases are 
considered attractive targets thanks to their good accessibility and prokaryotic exclusivity. 
The S. aureus, genome encodes two SPaseI homologues namely SpsA and SpsB. It 
appears that SpsA is inactive as it lacks the catalytic Ser and Lys residues (replaced by 
Asp and Ser, respectively). It is believed that SpsA has probably persisted as a non-
hydrolyzing enzyme already for a considerable period of time in S. aureus, as the active-
site mutations each necessarily involve changes to at least two nucleotides of the codon, 
and transitional forms of inactive enzyme must have preceded the formation of SpsA 
with a non-aspartyl replacement for the active-site Ser and a non-seryl replacement of the 
active site Lys (Cregg et al., 1996). The presence of an apparently catalytically inactive 
SpsA homologue is a conserved feature of all staphylococci with sequenced genomes 
(Sibbald et al., 2006). To date, it is not known whether the inactive SPase homologues 
contribute somehow to protein secretion in these organisms. The catalytically active 
SPase is SpsB which was shown to be essential for growth and viability of S. aureus 
(Cregg et al., 1996). Although the enzyme remains to be structurally characterized, a set of 
lipopeptide inhibitors were developed using the classical approach and were shown to 
inhibit the enzyme (Bruton et al., 2003). 
      
The objectives of this project were (i) to analyze the in vitro biochemical properties of the 
SPaseI of S. aureus, SpsB; (ii) to develop and validate an in vitro assay for high-throughput 
screening of potential inhibitors of SpsB and (iii) finally to screen small molecule 
compound libraries against this target, in the search for new classes of antibiotics. 
 
In this work, we purified SpsB and confirmed its in vitro activity on two selected 
substrates. The first was the native preprotein substrate IsaA precursor that is known to 
play a role in the virulence of S. aureus. The second was a synthetic decapeptide based on 
the signal peptide sequence of S. epidermidis preprotein (SceD precursor) with quencher 
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Dabcyl and fluorophore EDANS at its N- and C-terminus respectively. We confirmed 
that the substrates are cleaved at the predicted site following the “Ala-X-Ala” rule of 
SPase recognition and cleavage. We also designed and purified two truncated SpsB 
derivatives lacking most of the hydrophobic transmembrane residues. The truncated 
SpsB derivatives were identical in sequence except for the catalytic Ser replaced by an Ala 
in one of the truncated derivatives which we designated the truncated mutant (tr-mut-
SpsB). The other truncated derivative, in which catalytic Ser remained as such, was 
designated as tr-SpsB. We showed that tr-SpsB retained SPaseI activity as evidenced by 
processing of both the preprotein as well as the synthetic peptide substrate. These results 
demonstrated that the transmembrane anchor is not required for enzymatic activity of 
SpsB.  
 
The specific enzymatic activity (kcat/Km) of the full-length SpsB was found to be 
approximately 1850 M-1s-1 in the FRET assay using the synthetic SceD peptide. The 
kcat/Km value of SpsB obtained in this work using the SceD peptide (10-mer) is 
intermediate when compared to its specific enzymatic activity reported in literature using 
two other synthetic peptide substrates. Of the two synthetic peptide substrates described, 
one is an 11-mer based on the signal peptide region of maltose binding protein of E. coli 
(Zhong & Benkovic, 1998) and the other is a 13-mer based on the preprotein sequence 
data in S. aureus (Bruton et al., 2003). The kcat/Km values obtained for SpsB were 18.4 and 
4.2x105 M-1s-1 using the former and latter peptide, respectively (Bruton et al., 2003). To 
the latter synthetic peptide a fatty acid tail was added to mimic the hydrophobic signal 
peptide region of a natural SPaseI substrate which resulted in a better substrate for SpsB.  
 
The FRET assay with the synthetic peptide was used to compare the catalytic efficiencies 
of the full-length and the truncated derivative of SpsB while the truncated mutant served 
as a control. Notably, in this work we have shown that the specific enzymatic activity of 
the full-length SpsB is 30-fold higher, compared to tr-SpsB which has a kcat/Km value of 
59.4 ± 6.4 M-1s-1. This highlights the importance of the transmembrane segment residues 
for optimum activity of SpsB. Importantly we also showed that the presence of the non-
ionic detergent Triton X-100 is required for optimum in vitro activity of tr-SpsB, although 
it lacks most of the hydrophobic residues in the transmembrane segment. Additionally, 
the specific enzymatic activity of tr-mut-SpsB was determined to be 4 ± 0.8 M-1 s-1, which 
is not significant. The full-length SpsB has a 462-fold higher activity compared to the tr-
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mut-SpsB which confirms that the activity observed in the in vitro assay is specifically due 
to SpsB and not due to the background activity of LepB of E. coli (which was used as the 
host for overproduction of SpsB). 
 
We analyzed the in vitro behaviour of the full-length SpsB in terms of its pH requirement 
and stability. Compared to E. coli LepB which is active from pH 7 to 11, SpsB is capable 
of functioning at a wider pH range i.e., from pH 5 to 12. The optimum pH of SpsB was 
shown to be approximately 8, which is basic, as is the case for other SPases characterized 
in vitro and which is also in agreement with the catalytic mechanism. The specific 
enzymatic activity of SpsB was plotted as a function of pH to obtain the pH-rate profile. 
Interestingly, the pH-rate profile of the enzyme did not result in a typical bell shaped 
curve as we observed also another, smaller peak around pH 11. Hence, the pH-rate 
profile was fitted with the equation for a complex bell-shaped curve. The apparent pKa 
values for the free enzyme was determined to be approximately 6.6 and 8.7 with possibly 
another pKa around 11.8. The two shoulders in the pH-rate profile are a signature of the 
fact that there are three acid groups that are important and therefore four species: E, 
EH+, EH2+, EH3+, of which E and EH3+ are inactive. EH3+ is probably the enzyme with 
the catalytic Lys protonated (with a very abnormal low pKa); EH+ and EH2+ may be 
involved in the stabilisation of the active conformation. However, without the crystal 
structures of the extreme forms E and EH3+, one cannot say much more. So when the 
pH is raised to create E the enzyme is no longer active. 
 
We studied the effect of temperature (4 °C, 27 °C and 37 °C) on the stability of SpsB 
during storage for varying periods of time in the presence of a general protease inhibitor 
cocktail. SpsB was observed to be generally more stable in comparison with E. coli LepB 
stored under similar conditions (Talarico et al., 1991). However, upon prolonged storage, 
we observed the appearance of a smaller band, apart from that corresponding to the full-
length SpsB. We confirmed that this smaller band is the result of intermolecular self-
cleavage of SpsB as it did not appear when the SPase inhibitor arylomycin A2 was added 
to the purified protein sample. We also showed that self-cleavage of SpsB occurs 
following the “Ala-X-Ala” rule for SPase cleavage based on the N-terminal sequencing 
data of the self-cleavage product obtained. The self-cleavage product of SpsB still 
contains the catalytic Ser although it is at the penultimate end on the N-terminus of the 
protein. We then analyzed the activity of the self-cleavage product of SpsB in the FRET 
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assay but could not observe processing of the synthetic peptide under the standardized 
conditions in vitro.  
 
These results led to the interesting observation that the difference of only nine amino 
acids between the self-cleavage product of SpsB and the N-terminally truncated 
derivative (tr-SpsB) influenced their ability to be active or not. While the former was 
unable to process the synthetic peptide substrate in the FRET assay, the latter retained a 
significant activity. We believe that this difference is due to the lack of residues which are 
part of the conserved box B region of the signal peptidases in the self-cleavage product 
of SpsB. Many of these residues most likely reside in the substrate binding site of SpsB 
analogous to LepB. The nine additional residues preceding the catalytic Ser are probably 
required for the proper conformation of the enzyme.   
 
We then validated the FRET assay for screening compounds against SpsB. Initially, 
different conditions in the FRET assay were studied such as the concentration and 
compatibility of the different components of the reaction mixture, signal uniformity 
within a microplate and variations between intra-day and inter-day data. Based on these 
data the assay was standardized and in vitro inhibition of SpsB was demonstrated using 
the SPase inhibitor arylomycin A2. The SpsB-FRET assay was subsequently used to also 
demonstrate the suitability of a rationally designed peptide (Buzder-Lantos et al., 2009) 
for SPaseI-cleavage inhibition testing. We further showed that the preprotein processing 
of SpsB is blocked in the presence of SPase inhibitors such as arylomycin A2 and (5S,6S)-
6-[(R)-acetoxyethyl]-penem-3-carboxylate. The preprotein processing assay could be 
adapted for use as a confirmative assay in the search for SpsB inhibitors.  
 
Approximately 6,200 compounds were screened manually in the SpsB-FRET assay. The 
compounds were mostly small molecules from the chemical compound libraries 
belonging to CD3 and the Rega Institute and a few peptides based on in silico data. None 
of the compounds could inhibit SpsB to a considerable extent. Compounds that could 
not be analyzed properly due to interference with fluorescence (approximately 1 % of the 
total) in the FRET assay were analyzed in the preprotein processing assay. Again, none of 
these were found to be active against SpsB. The quality of the assay was assessed as 
previously described (Zhang et al., 1999) and was found to be reliable for screening. We 
also observed that the compounds selected from an in silico screen against the E. coli 
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SPase structure were able to inhibit this particular enzyme better than S. aureus SpsB, 
highlighting the subtle differences between the two enzymes but also emphasizing the 
need for the crystal structure of SpsB.  
 
Based on the above results, one obvious question that comes to mind is why was the 
success rate so low? This is in part due to the nature of the enzyme. SPasesI are regarded 
as difficult targets when it comes to finding effective inhibitors (Black & Bruton, 1998). 
There are very few good SPaseI inhibitors available as of now; this is in spite of the 
efforts of various groups including pharmaceutical giants who have worked in this area 
like Merck, GlaxoSmithKline, Procter and Gamble and Lilly laboratories. Secondly, the 
lack of structural information leaves us with not too many options but random screening 
for inhibitors against SpsB. The homology modelling of SpsB based on the structure of 
LepB is not reliable as there is less than 30 % sequence identity between the two 
enzymes. In addition, the basic properties of the enzyme (SpsB) such as the requirement 
for detergent (even for the truncated derivative) and self-cleavage activity makes it a 
difficult candidate for crystal structure determination. The group of Prof. Dr. Remy Loris 
(VUB, Brussels) set-up crystallization trials on SpsB and its derivatives obtained in this 
work using different conditions and also attempting several different approaches in 
pursuance of the structural information on SpsB. Unfortunately, none of the conditions 
or approaches resulted in obtaining crystals suitable for X-ray diffraction. Another 
possible reason for lack of hits could be due to the common selection criteria/filters 
applied while building the compound library. The rules for selection normally focus on 
drug-like properties of the compounds and therefore a particular compound library 
might or might not work on different targets. On the other hand the number of 
compounds screened in this work is limited to ~27,000 and it might be too early to 
conclude anything about the suitability of a particular compound library. Whether natural 
compounds like secondary metabolites from microbial sources would be better 
candidates for screening remains to be seen.   
 
The next step was to increase the throughput of the assay to be able to screen chemical 
compound libraries. Where possible, necessary changes were made in the protocol and a 
complete library of small molecules belonging to CD3 was screened. The assessment of 
assay quality based on the screening data reflected the robustness of the assay (Z’ of each 
plate screened ≥ 0.5; average Z’ = 0.73). Further analysis of the most active compounds 
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identified in the HTS resulted in the identification of at least one compound (JRD 2189) 
which could inhibit SpsB in the in vitro FRET assay (IC50= 51 µM). However, the 
compound was not active in the preprotein processing assay which confirms its low 
potency against the enzyme. We also showed that JRD 2189 inhibits E. coli LepB in the 
FRET assay. Weak inhibitors do not make good starting points as drug leads and are 
usually only pursued if they indicate a new mode of inhibition that can be exploited by 
other means. An example for a weak inhibitor of SPase that has been shown to have 
such a potential is the β-sultam inhibitor BAL0019193 (Luo et al., 2009). It therefore 
remains to be seen if molecular modelling in the active site of LepB looks positive or not. 
If the modelling data looks encouraging, only then would it be interesting to study 
structure activity relationship and possibly optimize the compound for better efficiency.  
 
Currently, CD3/Rega library compounds have not been tested by us directly on bacterial 
cells in phenotypic assays. Both whole cell approach and target based approach have 
advantages and disadvantages. In the first place, we have focused on the latter approach 
so that we do not miss out the compounds that are effective inhibitors but are not 
effective on whole cells due to their physicochemical properties or are prone to 
enzymatic modifications. The idea is to improve the solubility and drug-like properties of 
such hits to obtain useful antibiotics. Although there are no data from whole cell assays, 
we agree that it is interesting to test antibacterial activity of these compounds and this 
would be feasible when this test is automated as well.  
 
In essence, in this work, S. aureus SpsB was studied to gain a better understanding of its 
properties in particular and that of SPaseI in general.  In light of its potential use as a 
non-conventional antibiotic target, in vitro inhibition assays were developed. High-
throughput screening of a chemical compound library against SpsB yielded data of good 
quality confirming its suitability for this purpose, but unfortunately did not result in 
finding effective inhibitors.  
 
Nevertheless, SpsB remains an attractive target for deriving novel antibacterials, given the 
need for new drugs to combat multi-drug resistant strains. In the absence of structural 
data for SpsB, random screening continues to be an attractive approach for deriving 
novel antibacterials against S. aureus.  In addition, virtual screening using the structure of 
LepB could possibly aid in finding certain broad spectrum inhibitors. Finally, when the 
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crystal structure of SpsB is solved the data could help significantly in the drug discovery 
process and the in vitro assays developed in this work will continue to play an important 
part.  
 
Among the questions that will need to be addressed in future are:  
 How different is the 3D structure of the active site of SpsB in comparison with 
LepB?  
 What could be the possible role of signal peptidase like-protein SpsA in S. aureus? 
 Finally, it remains to be seen whether S. aureus will continue to emerge stronger 
and persist by developing resistance to SPase inhibitors as well? 
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